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 The process of vesicular exocytosis is a fast, tightly regulated and Ca2+-triggered 
event mediated by SNARE complex formation. Although it is known that factors like 
Munc18, Munc13 and CAPS are important in setting up the SNARE core fusion machinery 
in a process called priming, the underlying molecular mechanism is not well understood. 
Munc13 is of critical importance in priming synaptic vesicles (SVs) for release, and SV 
exocytosis in hippocampal synapses is completely shut down in the absence of Munc13-1 and 
Munc13-2, whereas in the case of synaptic dense core vesicles (DCVs) the synaptic 
preference of DCV release is lost. CAPS was originally identified as a factor which 
reconstitutes secretion in permeabilised neuroendocrine cells, and has since been recognised 
as important in regulated release of DCVs in C. elegans and large dense core vesicles 
(LDCVs) in neuroendocrine chromaffin cells, as well as in SV exocytosis in neurons. 
Although overexpression studies had also implicated Munc13s in LDCV release in 
chromaffin cells, in this cell type no LDCV release deficit had ever been demonstrated in 
their absence, and CAPSs proteins had been suggested to be the main regulators of LDCV 
exocytosis. To gain a more complete picture of potential differences in the regulation of SV 
and LDCV exocytosis, we investigated the role of different Munc13 isoforms in chromaffin 
cell LDCV exocytosis. This study is the first to report a deficit in chromaffin cell LDCV 
exocytosis in the absence of Munc13 isoforms. The ubiquitous (ub)Munc13-2 is the dominant 
isoform in murine chromaffin cells, and its deletion results in reductions of 60% of the fast 
burst component, of 52% of the slow burst component and of 72% of the sustained 
component, which is a more drastic reduction of release than in chromaffin cells of CAPS-
deficient mice. Munc13-1 expression is low in perinatal adrenal glands, and its deletion alone 
did not result in significant changes in exocytosis, however its function in LDCV release 
became apparent in the absence of Munc13-2. Munc13-1 appears to mostly contribute to the 
slow burst and sustained component of release. By contrast, deletion of Baiap3, another 
Munc13 isoform with relatively high expression in adrenal medulla, did not lead to changes 
in LDCV exocytosis and its overexpression could not rescue the release deficit of Munc13-
1/2 deficient cells. The remaining Munc13 isoforms, bMunc13-2, Munc13-3 and Munc13-4 
are not expressed in perinatal adrenal glands and do not contribute to LDCV exocytosis in 
this cell type. Taken together, our findings show that ubMunc13-2 and Munc13-1 regulate 
LDCV exocytosis in chromaffin cells. Thus, at least in mammals, both Munc13s and CAPS 
	  	  
4	  	  
proteins are critical in the regulation of both SV and LDCV exocytosis in neurons as well as 






1.1 The Brain, Neurons and Synapses 
The brain is the central organ for information processing in humans. The human brain 
contains ≈ 1011 neurons which form an interconnected network enabling the reception and 
processing of information as well as the execution of responses. A typical neuron comprises 
four functional regions, namely a cell body, an axon, several dendrites and a pre-synaptic 
terminal. Dendrites can arborize and specialises in receiving signals from other neurons. The 
axon extends from the cell body to send electrical signals to other neurons. A typical neuron 
has a resting membrane potential of -60 mV to -70 mV. The resting membrane potential is 
maintained by the Na+/K+-ATPase and the fact that ion channels that span the neuronal 
plasma membrane are more permeable to K+ than to Na+ at the resting potential. Voltage-
gated channels respond to changes in membrane potential by a conformational change, 
opening the channels and allowing for ion flux that is specific for the channel and in 
accordance to the electrochemical gradient across the membrane. When the membrane is 
depolarised to above a certain threshold, an action potential is generated which propagates 
along the axon. When the action potential reaches the pre-synaptic terminal of a chemical 
synapse, it causes the opening of voltage-gated Ca2+ channels and results in Ca2+ influx into 
the pre-synapse. This leads to an increase in pre-synaptic [Ca2+] and triggers the fusion of 
synaptic vesicles with the plasma membrane, releasing their content, neurotransmitter, into 
the synaptic cleft. Neurotransmitter molecules traverse the synaptic cleft and bind to post-
synaptic receptors, including ligand-gated ion channels. These channels then open or close, 
and thus the electrical signal is propagated to the post-synaptic cell (Kandel et al., 2013). 
 The excitation-secretion-coupling in synapses is extremely efficient, with Ca2+-
triggered vesicle fusion lagging behind the influx of Ca2+ by a mere 60 µs (Sabatini and 
Regehr, 1996). This efficiency is crucial for the ability of neurons to encode and compute 
information in neural circuits, for example via processes such as short-term synaptic 
plasticity (Abbott and Regehr, 2004). The maintenance of the extremely short delay relies on 
a fusion machinery that is highly specialised for fast and synchronised release. The soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins constitute the 




1.2 Synaptic Vesicle Cycle  
 
Fig.1.1 The synaptic vesicle cycle (Jahn and Fasshauer, 2012) . 
 The synaptic vesicle (SV) cycle is shown in Fig. 1.1. Synaptic vesicle precursors 
(SVP) are synthesised in the cell soma. They are transported anterogradely along the axon to 
the synaptic domain of the neuron by microtubule-dependent trafficking mediated by the 
kinesin family of proteins (Maeder et al., 2013).  A reserve pool of SVs is maintained in the 
active zone for mobilisation on demand (Denker and Rizzoli, 2010). This pool is thought to 
be maintained in part by synapsins, which tether SVs to each other and to actin, but are able 
to dissociate from both upon phosphorylation (Fornasiero et al., 2012). During maturation, 
SVPs acquire the correct complement of membrane proteins and neurotransmitters are filled 
into SVs at the pre-synapse. Mature SVs are then translocated to the site of neurotransmitter 
release, the active zone (AZ), where they are docked and primed. Docking refers to the 
process by which secretory vesicles are rendered in contact with or in very close proximity to 
the plasma membrane and is based on morphological data obtained by electron microscopy 
(EM) (Verhage and Sorensen, 2008). Priming is the process by which vesicles attain a state 
which enables them to be released without further maturation steps at the arrival of the Ca2+ 
signal, and is based on physiological data. Priming is thought to occur after docking, but 
whether they represent partially overlapping steps or even the same step remains disputable. 
When the pre-synaptic membrane is depolarised, voltage-gated Ca2+ channels open and Ca2+ 
influx occurs down the electrochemical gradient across the membrane. Ca2+ ions bind to Ca2+ 
sensor proteins, e.g. synaptotagmins, which undergo conformational changes leading to 
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fusion of SVs with the plasma membrane. After fusion, endocytosis takes place in the 
vicinity of AZs for membrane retrieval.  
 
1.3 Vesicle Pool Dynamics  
 The concept of the existence of dynamic vesicle pools is useful for explaining diverse 
physiological phenomena of SV release, including short-term plasticity (Zucker and Regehr, 
2002). The total number of SVs contained per synapse in hippocampal excitatory neurons is 
estimated morphologically to be around 100-200 (Schikorski and Stevens, 1997). The 
classical model of synaptic vesicle pools contains the readily releasable pool (RRP), the 
recycling pool (RP) and the resting pool (RtP), the last of which is alternatively known as the 
reserve pool (Alabi and Tsien, 2012; Denker and Rizzoli, 2010). The RRP consists of 
vesicles that are ready to undergo fusion once the Ca2+ signal arrives. Thus, they have the 
highest release probability and are thought to be docked and primed at the AZ. The RRP 
consists only of 5-9 SVs in a hippocampal bouton (Murthy and Stevens, 1999) and is 
depleted in a few seconds with 10-40 Hz stimulation (Stevens and Williams, 2007). The 
number of RRP vesicles can be estimated by application of hypertonic sucrose (0.5 M, 5s) 
(Rosenmund and Stevens, 1996). This method, although non-physiological, has the 
advantage over the use of action potential-triggered release that the mechanism of 
hyperosmotic release is not Ca2+-dependent (Geppert et al., 1994; Rosenmund and Stevens, 
1996), thus circumventing the interference of the resting RRP size by concurrent Ca2+-
accelerated vesicle replenishment into the RRP (Smith et al., 1998). The size of the RRP and 
the vesicular release probability of SVs in the RRP have an impact on the efficiency of 
neurotransmission. After depletion of the RRP, the RP is released. The size of the RP is 
typically around 3 times that of the RRP (Murthy and Stevens, 1999). During high frequency 
stimulation, the RP is released with a time constant slower than the RRP, indicating that 
vesicles in the RP need to undergo further maturation steps before becoming release-
competent. The transitions for RP vesicles to the release-ready state provide opportunities for 
regulation (Alabi and Tsien, 2012). Replenishment from the RP to the RRP is accelerated not 
only by activity-dependent increases in intracellular Ca2+  but can also be enhanced by 
protein kinase C activation (Stevens and Sullivan, 1998). The RtP represents a pool that 
remains release-reluctant during prolonged stimulation when vesicle turnover is already 
maximal (Harata et al., 2001; Li et al., 2005), although evidence had been presented to show 
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that in some preparations (e.g. the frog neuromuscular junction), using physiological but 
prolonged stimulation, all vesicles participate in release (Betz and Henkel, 1994; Ceccarelli et 
al., 1972). The RtP pool constitutes around 50-85% of all vesicles (Fernandez-Alfonso and 
Ryan, 2008; Harata et al., 2001), and can be mobilized by cellular signalling pathways, such 
as protein kinase A stimulation (Kuromi and Kidokoro, 2005) and cyclin-dependent kinase 
(CDK5) inhibition (Kim and Ryan, 2010). The RP and the RtP are thought to be spatially 
intermixed throughout the synaptic bouton (Harata et al., 2001; Rizzoli and Betz, 2005). It is 
suggested that newly endocytosed vesicles belonged to the RP and have high mobility, which 
contributes to their relative readiness for release (Denker and Rizzoli, 2010; Kamin et al., 
2010). In the absence of stimulation, these vesicles integrate into the RtP (Rizzoli and Betz, 
2004) and become more immobile, thus more reluctant to release (Kamin et al., 2010). 
Modulation of pool sizes and dynamics of conversions between pools affect synaptic 
reliability and synaptic strength (Alabi and Tsien, 2012). 
 
1.3.1 Vesicle Pool Dynamics in Chromaffin Cells 
 The adrenal medullary chromaffin cell is a well characterised model system for 
studying neurosecretion. Chromaffin cells contain large dense core vesicles (LDCVs), and 
secrete catecholamines, which mediate the fight or flight response and are involved in a 
variety of stress and anxiety-related responses. In chromaffin cells, vesicular exocytosis, 
which causes an increase in the membrane surface area, can be monitored by capacitance 
measurement across the surface of the whole cell at high time resolution (Neher and Marty, 
1982). Carbon fibre amperometry, which measures the amount of oxidisable secretion 
electrochemically, is often used simultaneously alongside capacitance measurements to 
indicate the secretion of oxidisable catecholamines (Bruns, 2004). Amperometry is also 
useful in measuring fusion pore dynamics and detecting the release of single vesicles.  
 Various vesicle pools had been identified in chromaffin cells. Vesicle pools can be 
identified using a strong stimulus that depletes the RRP with such fast kinetics that enables its 
isolation from slow replenishment processes (Sorensen, 2004). Flash photolysis of a 
photolabile Ca2+-chelator can be used to achieve a sudden homogeneous increase of [Ca2+] 
throughout the cell from hundreds of nanomolar to tens of micromolar [Ca2+] (Naraghi et al., 
1998). This increase in [Ca2+] is independent of Ca2+ channels and thus exocytosis triggered 
with this method does not reflect the localisation of vesicles with respect to Ca2+ channels but 
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the kinetic characteristics inherent to vesicle pools. Analysis of release kinetics showed, that 
within 1s of the flash, a sum of two exponentials was necessary to fit the membrane 
capacitance increase, indicating that two kinetically distinct pools of vesicles exist (Xu et al., 
1998). The faster pool is released with a time constant of ≈ 20-40 ms at [Ca2+] = 20 µM and 
is regarded as the RRP, while the slower pool (slowly-releasable pool, SRP) is released with 
a time constant of ≈ 200-400 ms at [Ca2+] = 20 µM (Sorensen, 2004). Together, these two 
pools are termed the exocytotic burst. After depletion of this burst, further slower release (so-
called sustained release), which has a near constant rate of release, ensues. The difference in 
release kinetics of the pools is thought to indicate the degree of maturation of the different 
pools. The sizes of the RRP and the SRP show a biphasic relationship with pre-flash [Ca2+] 
(Fig. 1.2A-C), with maximal pool sizes at ≈ 600 nM of pre-flash [Ca2+], equivalent to around 
140 vesicles per pool (Voets, 2000) assuming that the release of one vesicle causes a 
capacitance increase of 1.3 pF (Moser and Neher, 1997). Assuming a parallel pool model 
(PPM) of release (Fig. 1.3B), in which both the RRP and SRP are releasable but each with a 
distinct Ca2+ sensor requiring the binding of three Ca2+ ions to trigger release, the transition 
from the SRP to the RRP is thought to be Ca2+-independent due to the unaltered contribution 
of the two pools to the burst at pre-flash intracellular [Ca2+] under 600 nM (Fig. 1.2D) 
(Voets, 2000). Beyond this range, the exocytotic burst decreases in size with increasing 
[Ca2+] due to loss of vesicles through exocytosis. In the same study, the authors determined 
that both the size of the exocytotic burst and the fraction of RRP to the burst are not affected 
by post-flash [Ca2+]. Recently, it has been suggested that an alternate model of release, the 
sequential pool model (SPM) (Fig. 1.3A), can recapitulate release from chromaffin cells as 
well as or better than the PPM (Walter et al., 2013). In particular, the SPM can more 
parsimoniously simulate the faster recovery of the RRP triggered by a second flash stimulus 
after depletion of both pools using a first flash (Pinheiro et al., 2013). This model also 
describes the concurrent increase in the fast time constant of release and proportional shift of 
the SRP to the RRP detected in a synaptobrevin-2 mutant with defective C-terminal 
interaction sites (Walter et al., 2010). The SPM further predicts the existence of a Ca2+-
dependent catalytic step, which endows a pool of non-releasable vesicles with RRP status, 
with the RRP being the only releasable pool of vesicles in this model. Interestingly, the 
authors found that if the PPM was modified to incorporate a Ca2+-dependent catalytic step for 
the SRP to RRP conversion, the PPM can also account for the fast recovery in the dual-flash 




Fig. 1.2 Ca2+-dependence of the (A) exocytotic burst, (B) RRP, (C) SRP and the (D) 
contribution of the RRP to the exocytotic burst in chromaffin cells (Voets, 2000). 
 
Fig. 1.3 (A) Sequential and (B) parallel models of secretion (Walter et al., 2013). 
 Because in Ca2+ uncaging experiments the post-flash [Ca2+] levels can not only trigger 
exocytosis, but at [Ca2+] of >50 µM elicit rapid endocytosis (Sorensen, 2004), and at 
concentrations of > 100 µM result in the release of an “intermediate” pool of vesicles which 
do not contain catecholamines (Xu et al., 1998), an accurate control of both pre- and post-
	  	  
11	  	  
flash [Ca2+] is required for studying the exocytosis of catecholamine-containing vesicles from 
chromaffin cells.  
Unlike Ca2+ uncaging by flash photolysis, short trains of depolarisations cause high 
local [Ca2+] in close proximity to Ca2+ channels, referred to as Ca2+ microdomains (Neher, 
1998). The high [Ca2+] is sensed by vesicles co-localised with Ca2+ channels and they are 
consequently rapidly released. This pool of vesicles is known as the “immediately releasable 
pool” (IRP) of vesicles (Horrigan and Bookman, 1994; Voets et al., 1999). Using cross-
depletion experiments, it had been shown that the IRP is a component of the RRP and 
represents around 25% of RRP vesicles (Voets et al., 1999). 
 
1.4 Comparison between Synaptic Vesicle Exocytosis and Large Dense Core Vesicle 
Exocytosis 
 Numerous features distinguish SV and LDCV exocytosis from each other. The 
distinct modes of biogenesis and difference in release kinetics between these two types of 
organelles imply that the molecular machineries underlying vesicle delivery to the plasma 
membrane and fusion of these two types of vesicles might be different (Xu and Xu, 2008).   
SVs contain neurotransmitters such as glutamate, γ-aminobutyric acid (GABA), 
glycine, acetylcholine and serotonin. Their diameters are around 50 nm (Kriebel et al., 1986) 
and they appear as small clear vesicles in electron microscopy. In contrast, LDCVs contain 
mainly neuropeptides and hormones, are 100-300 nm in diameter (Grabner et al., 2006) and 
are observed as electron dense organelles. In synapses the dense core vesicle (DCVs) 
diameter measures around 70 nm (Fig. 1.4). They can also be observed at low numbers in the 






Fig. 1.4 Dense core vesicles and synaptic vesicles (SV) in hippocampal synapses. SV 
clusters can be seen. Arrowheads indicate DCVs. Scale bar, 100 nm (van de Bospoort et al., 
2012). 
 
1.4.1 Biogenesis of SVs and LDCVs 
 A large number of neuropeptides and other cargo are packaged into each LDCV in a 
highly condensed manner to ensure efficient storage and osmotic inertness (Xu and Xu, 
2008). Immature LDCVs are generated de novo by budding at the trans-Golgi network 
(TGN) (Santos et al., 2009).  The granin family of proteins, e.g. chromogranins and 
secretogranins, are secreted together with neuropeptides from LDCVs and are thought to 
facilitate budding from the TGN (Xu and Xu, 2008). Granins bind Ca2+ with low affinity. 
Ca2+ binding leads to aggregation of granins which induces wrapping of the TGN membrane 
around the aggregates, causing membrane deformation and budding (Xu and Xu, 2008). The 
role of granins in LDCV biogenesis is exemplified by the reduced number of LDCVs in 
PC12 cells (a cell line derived from rat pheochromocytoma, a cancer of the adrenal medulla) 
following chromogranin A downregulation and formation of LDCV induced by 
overexpression of chromogranin A in fibroblasts (Kim et al., 2001). Immature LDCVs 
undergo homotypic fusion that requires syntaxin-6 and synaptotagmin IV. In PC12 cells, 
synaptotagmin IV depletion inhibits homotypic fusion and results in decreased 
endoproteolytic activation of prohormone convertase 2, which is required for processing of 
secretogranin II, a DCV cargo (Ahras et al., 2006). Missorted proteins are removed by 
budding, for example, using adaptor protein (AP)-1/clathrin-coated vesicles (Klumperman et 
al., 1998). Neuronal adaptor protein-3 (AP-3), a multi-subunit protein, pinches off smaller 
vesicles from the larger immature vesicles during maturation, thus regulating the sizes and 
quantal content of LDCVs in chromaffin cells (Grabner et al., 2006). In addition, Rab3, a 
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vesicular GTPase that has been identified with a role in tethering vesicles, appears to be 
important in vesicle biogenesis in chromaffin cells, as the total number of LDCVs per cell 
section was halved in mice lacking all four Rab3 isoforms (Schonn et al., 2010). LDCVs are 
replenished by KIF-1A-dependent anterograde transport of granules generated from the 
trans-Golgi network (Zahn et al., 2004). Furthermore, single LDCVs can also undergo 
secretion without releasing all of their contents before re-sealing to form a granule (Perrais et 
al., 2004). In hippocampal neurons, only 20% of DCVs were observed at synapses, while 
65% of release occurred at synaptic sites, which led to the suggestion that neuronal DCVs are 
mobilised to release sites during activity, where they are then docked and primed for release 
(van de Bospoort et al., 2012). 
 Unlike the LDCVs, SVs are supplied locally near their site of release, the AZ, so that 
high supply rates can be sustained during high synaptic activity. SV proteins are thought to 
be synthesised in the cell soma and transported to nerve terminals by membrane carriers via 
fast axonal transport along microtubules (Santos et al., 2009). They may be delivered to the 
plasma membrane and undergo series of exo-endocytic cycles, during which they become 
sorted into SVs (Santos et al., 2009).  After fusion, membrane retrieval occurs by endocytosis 
near the AZ. Clathrin-mediated endocytosis represents a major pathway of endocytosis. 
Membrane invagination at the outer margins of the AZ causes the appearance of clathrin-
coated buds, and fission is mediated by the GTPase dynamin (Conner and Schmid, 2003). 
The clathrin coat is composed of an outer layer of clathrin and an inner layer of adaptor 
proteins, such as adaptor protein-2 (AP-2) (Saheki and De Camilli, 2012). Uncoating of the 
clathrin and adaptor coat occurs rapidly after fission, is ATP-dependent, and requires Hsc70 
ATPase and its cofactor auxilin (Yim et al., 2010). Uncoated vesicles are rapidly recruited 
into SV clusters for re-use (Saheki and De Camilli, 2012). SVs are also retrieved through 
bulk endocytosis, followed by the formation of endocytic vacuoles which subsequently 
generate SVs through unknown mechanisms. Lastly, SVs are proposed to be recycled 
through “kiss-and-run”, in which a transient fusion pore forms and close rapidly without 
collapse of the vesicle into the plasma membrane (Saheki and De Camilli, 2012).  
 
1.4.2 Docking of SVs and LDCVs 
 Different criteria of docking can be employed by investigators, depending on the 
techniques and biological systems used, as well as the degree of stringency deemed 
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appropriate for the study. Some authors consider vesicles located within a certain distance 
(e.g. 30 nm) from the plasma membrane as docked, while others count only vesicles forming 
a “contact patch” with the plasma membrane as docked (Verhage and Sorensen, 2008). 
Various proteins have been implicated in the docking of SVs and LDCVs. Munc18 is 
required for docking of both SVs and LDCVs. Chromaffin cells from Munc18 null mutant 
mice show a 10-fold reduced secretion and a concomitant reduction in the number of 
morphologically docked LDCVs (Voets et al., 2001). Mice heterozygous for Munc18 show 
30-50% reduction in the number of docked SVs (Toonen et al., 2006b) in autaptic 
hippocampal neurons and in docked LDCVs in chromaffin cells (Toonen et al., 2006a). In 
unc-18 mutant nematodes the number of docked SVs is reduced to 36% of wild-type at 
neuromuscular synapses (Weimer et al., 2003). Thus, Munc18 is an established docking 
factor for both LDCVs and SVs. 
 Munc18 interact closely with syntaxin-1, both in a binary complex and when 
syntaxin-1 is in the SNARE complex. Botulinum neurotoxin C (BoNT/C) cleavage of 
syntaxin-1 in chromaffin cells results in a strong reduction of the number of docked LDCVs 
but no apparent changes in SV docking in synaptic terminals of autaptic hippocampal 
neurons, despite a near total abrogation of release in both cell types (de Wit et al., 2006). In 
agreement with this finding, the number of docked insulin granules (a type of LDCV) is 
decreased in pancreatic β-cells from syntaxin-1A knockout (KO) mice (Ohara-Imaizumi et 
al., 2007). However, using a high pressure freezing (HPF) technique, which is thought to 
render a more accurate picture of ultrastructural morphology, a strong docking defect was 
observed in both excitatory cholinergic and inhibitory GABAergic neurons of syntaxin null 
mutant worm at the AZ and peri-synaptically, showing that syntaxin is required for SV 
docking in C. elegans synapses (Hammarlund et al., 2007). The same group also reported that 
docking of synaptic dense core vesicles (DCV), which are similar to LDCVs and releases 
neuropeptides and catecholamines from neurons, is dependent on syntaxin (Hammarlund et 
al., 2008), corroborating previous data acquired using chemical fixation. Taking the available 
evidence into consideration, it may be said that syntaxin is essential for docking LDCVs onto 
plasma membranes, but its role in SV docking remains unclear due to conflicting results 
reported using different methods in different species. It is worth noting that in mice 
expressing open syntaxin-1B in a syntaxin-1A KO background, docking is intact for SVs in 
neurons but not for LDCVs in chromaffin cells, demonstrating that the Munc18/closed 
	  	  
15	  	  
syntaxin complex is required for LDCV docking in chromaffin cells but not for SVs in 
synapses (Gerber et al., 2008).  
 Another t-SNARE protein, SNAP-25, was shown by HPF to be required for docking 
in both isolated chromaffin cells and intact adrenal glands (Fig. 1.5) (de Wit et al., 2009), 
while synaptobrevin-2 was not essential for LDCV docking in chromaffin cells (conventional 
fixation, (Gerber et al., 2008)). Chromaffin cells from SNAP-25 KO mice showed a less 
severe docking phenotype than Munc18- and syntaxin-1-deficient mice (de Wit et al., 2009). 
Moreover, chromaffin cells from synaptotagmin-1 null mice exhibited a strong docking 
defect in the 2009 study (de Wit et al., 2009). Contrary to the standard SNARE hypothesis of 
vesicle docking and fusion where synaptotagmin binds to the assembled SNARE complex 
(Sollner et al., 1993a), it was thus proposed that synaptotagmin-1 is the vesicular protein that 
mediates the interaction with the syntaxin-1/SNAP-25 acceptor complex to accomplish 
docking (de Wit et al., 2009). Another study showed that synaptobrevin cleavage by 
botulinum neurotoxin D (BoNT/D) perturbed LDCV docking in live PC12 cells as measured 
by total internal fluorescence microscopy (TIRF) and EM of cells fixed using HPF (Wu et al., 
2012). The authors of this study described that the N-terminus of synaptobrevin was 
important for docking, and thus proposed that N-terminal assembly of trans-SNARE proteins 
underlies docking. In addition to this, Rab3 GTPases have also been implicated in LDCV 
docking. Overexpression of Rab3A in chromaffin cells increases docking by ≈ 60% (van 
Weering et al., 2007). However, in chromaffin cells deficient for all four isoforms of Rab3, 
the total number of vesicles per cell section was reduced by ≈ 50%, but no changes were 
observed in the number of docked vesicles (Schonn et al., 2010). Another Rab GTPase, 
Rab27, and its effector granuphilin, may mediate LDCV docking in multiple systems, 
including PC12 cells (Tsuboi and Fukuda, 2006), pancreatic β-cells  (Kasai et al., 2005) and 




Fig. 1.5 Docking deficit in SNAP-25 KO chromaffin cells as an example of a docking 
phenotype. (A-B) Chemically fixed chromaffin cells from SNAP-25 WT and KO cells. (C-D) 
Fixation by high pressure freezing in SNAP-25 WT and KO cells (modified from (de Wit et 
al., 2009). 
 Munc13s and CAPS have been established as priming factors for SVs (Augustin et 
al., 1999b; Varoqueaux et al., 2002) and LDCVs (Liu et al., 2010; Zhou et al., 2007), 
respectively. The contributions of Munc13s and CAPS in docking these two types of vesicles 
will be discussed in the sections “Role of Munc13 Isoforms in Priming and Docking” and 
“Role of CAPS in Priming and Docking”.  
  
1.5 Mechanisms of Fast Vesicular Exocytosis 
1.5.1 SNARE Proteins as the Core Fusion Machinery 
Fusion of SVs with the pre-synaptic plasma membrane is an extremely fast and tightly 
regulated membrane fusion event (Wojcik and Brose, 2007). The excitation-secretion 
coupling occurs within 1 ms (Sabatini and Regehr, 1996) and is strictly dependent on the 
intracellular [Ca2+]. Although SV fusion events, like other cellular membrane fusion events, 
are dependent on SNARE proteins, a specialised set of regulatory proteins are required for 
fusion at this extraordinary speed and for the tight coupling to Ca2+ influx.    
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 The importance of SNARE proteins in vesicular fusion was realised when their 
proteolytic cleavage by clostridial neurotoxins was found to block different kinetic 
components of release (Banerjee et al., 1996; Capogna et al., 1997; Lawrence et al., 1997; 
McMahon et al., 1992). In chromaffin cells, botulinum neurotoxin (BoNT) serotype E, which 
cleaves the terminal 26 amino acids of SNAP-25, completely blocked all components of 
release induced by uncaging of Ca2+, while BoNT/A, which cleaves 17 amino acids 
upstream, reduced mainly the slower component of release and caused a slower release rate 
of the faster component, the exocytotic burst (Xu et al., 1998). BoNT/C, which cleaves 
SNAP-25 at a site one amino acid downstream of the BoNT/A cleavage site and also cleaves 
syntaxin, caused a complete block of all release components, indicating that syntaxin-1 is 
essential for exocytosis in chromaffin cells. Finally, tetanus toxin (TeNT) and BoNT/D, 
which cleaves synaptobrevin, also reduced all components of release (Xu et al., 1998). These 
studies thus highlight the essential role of SNARE proteins in exocytosis in neurosecretory 
cells.   
 In neurons and chromaffin cells, the SNARE proteins syntaxin-1, SNAP-25 and 
synaptobrevin-2 constitute the core fusion machinery. SNARE proteins are mechanistically 
highly conserved through evolution and are characterised by the presence of a SNARE motif, 
which forms an α-helix (Kloepper et al., 2007). The SNARE motifs of Syntaxin-1, SNAP-25 
and synaptobrevin-2 readily form a parallel four-helix bundle, which forms the core of a 
stable heterotrimeric complex called the SNARE complex (Fig. 1.6). The four-helix bundle is 
arranged into 16 layers contributed by highly conserved amino acid side chains facing the 
core of the bundle (Fasshauer et al., 1998). Syntaxin-1 and SNAP-25 are known as t(target)-
SNAREs because of their plasma membrane localisation, while synaptobrevin-2 is known as 
the v(vesicular)-SNARE because of its vesicular localisation (Rothman, 1994; Sollner et al., 
1993b). SNAREs can also be classified into R-SNAREs (e.g. synaptobrevin-2) or Q-
SNAREs (e.g. SNAP-25, syntaxin-1) according to the amino acid (arginine and glutamine, 
respectively) that they contribute at the polar layer 0 of the core of the SNARE complex 
(Fasshauer et al., 1998). Both syntaxin-1 and synaptobrevin-2 contribute one SNARE motif, 




Fig. 1.6 Structure of the SNARE complex and the domain structures of three SNARE 
proteins SNAP-25, syntaxin-1 and synaptobrevin-2 (modified from (Jahn and Fasshauer, 
2012)).  
Both syntaxin-1 and synaptobrevin-2 have transmembrane regions (TMRs) at their C-
terminal region, which anchor them in the membrane (Fig. 1.6). In contrast, SNAP-25 lacks a 
TMR and is anchored in the plasma membrane via palmitoylated cysteine residues at the 
linker between its two SNARE motifs. Apart from the TMR and the SNARE motif (also 
called the H3 domain), syntaxin-1 harbours also an autonomously-folding antiparallel three-
helix bundle called the Habc domain (Fernandez et al., 1998; Lerman et al., 2000). This 
three-helix bundle folds back onto the syntaxin-1 SNARE motif to form the closed 
conformation of syntaxin-1. In this conformation, access to the syntaxin-1 SNARE motif is 
limited and core complex formation cannot take place (Dulubova et al., 1999; Misura et al., 
2000). Syntaxin-1 contains also the N-peptide, which is situated at the very end of the N-
terminus, and is important for interaction with Munc18 (Dulubova et al., 2007; Khvotchev et 
al., 2007; Shen et al., 2010). Structurally, syntaxin exhibits alpha-helicity, while SNAP-25 
and synaptobrevin are largely unstructured, and are folded upon contact with their binding 
partners when they form the SNARE complex (Fasshauer et al., 1997; Wiederhold and 
Fasshauer, 2009).   	   Membrane fusion requires a considerable amount of energy because two negatively 
charged and inherently stable membranes have to be brought together. The “zippering” of 
SNARE motifs from the membrane-distal N-termini towards the membrane-proximal C-
termini into a four-helix bundle is highly exergonic and is thought to provide the energy for 
bringing the vesicular membrane and the plasma membrane into close apposition and for 
initiating fusion of both lipid bilayers (Hanson et al., 1997; Pobbati et al., 2006). In a study 
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using surface forces apparatus (SFA) in which two lipid bilayers each reconstituted with 
neuronal t- or v-SNARE proteins were allowed to approach each other, it was estimated that 
SNARE complexes started to form when the bilayers were around 8 nm apart and at this 
distance was able to form stable complexes in tens of seconds (Li et al., 2007). SNARE 
complex assembly is thought to start with the formation of a syntaxin-1/SNAP-25 
heterodimer which is called an acceptor complex. Addition of synaptobrevin to this 
preformed acceptor complex accelerated SNARE complex formation when compared to 
sequential addition of the three SNARE proteins (Pobbati et al., 2006). The N-terminal of the 
acceptor complex provides a binding site for the binding of the N-terminus of synaptobrevin, 
and SNARE zippering follows to form the trans-SNARE complex. This site can be stabilised 
by a C-terminal synaptobrevin fragment which prevents the association of a second syntaxin-
1 molecule to the acceptor complex. Li et al. showed that the SNARE complex formed only 
partially, with 12-25 membrane-proximal residues still unstructured, and the authors suggest  
that the negative residues in this unstructured region may cooperate electrostatically with the 
negative membrane to prevent full SNARE complex zippering (Li et al., 2007). Because 
syntaxin-1 is a somewhat promiscuous protein (Rizo and Sudhof, 2012), complexes other 
than the 1:1 syntaxin-1/SNAP-25 acceptor complex are also possible. Syntaxin-1 also forms a 
2:1 heterotrimer with SNAP-25 (Fasshauer et al., 1997), a 2:2 tetramer with the N-terminal 
SNARE motif of SNAP-25 (Misura et al., 2001a) and a homotetramer (Misura et al., 2001b). 
Thus, synaptobrevin competes with these alternative species to form the productive SNARE 
complex. 
 Whether SNARE complex formation releases sufficient energy for membrane fusion 
is an important question. Various groups have attempted to address this question by 
measuring the energy released by SNARE complex formation. Using single molecule 
dynamic force spectroscopy and SFA measurements, the energy released from SNARE 
complex formation measured around 23-35 kBT (equivalent to 14-20 kcal/mol) (Li et al., 
2007; Liu et al., 2009). These measurements are close to but lower than the energy required 
(40-50 kBT) for the formation of stalk-like states between the two bilayers (Kozlovsky and 
Kozlov, 2002), although the activation energy for fusion has not been precisely determined 
and is in the range of 40-200 kBT (van den Bogaart et al., 2010). Accordingly, the formation 
of only a few SNARE complexes would be sufficient for the initiation of membrane fusion. 
In another study using isothermal calorimetry to directly profile energy changes during 
progressive mixing (by injection) of SNARE proteins, the energy released was estimated to 
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be about 11 kcal/mol (equivalent to ≈ 18.5 kBT), which would call for a larger number of 
SNARE complexes to be formed for fusion to occur or be initiated. Based on a variety of 
methods in both in vitro and in vivo systems, including single vesicle fusion assays with 
planar membranes and detection of docking and fusion events by TIRF (Domanska et al., 
2010), fusion assays with purified synaptic vesicles and detection of lipid- and content-
mixing (van den Bogaart et al., 2010), capacitance measurement after flash photolysis of 
caged Ca2+ in chromaffin cells (Mohrmann et al., 2010) and re-expression of pHluorin-tagged 
synaptobrevin in synaptobrevin cellubrevin double-deficient hippocampal neurons to rescue 
exocytosis (Sinha et al., 2011), it has been suggested that at least 1 to 3 SNARE complexes 
are required for fusion to occur. After fusion has occurred, the SNARE complex is in the cis- 
configuration and requires the AAA ATPase N-ethylmaleimide sensitive factor (NSF) and its 
cofactor α- and β-SNAP for dissociation, so that they can be recycled for a new round of 
fusion (Banerjee et al., 1996; Burgalossi et al., 2010; Littleton et al., 2001).  
 Although the essential role of SNARE proteins in exocytosis is undisputed, the 
precise reaction mechanism which takes place to execute fast exocytosis has not been clearly 
defined. For instance, in vitro SNARE-mediated liposome fusion lasts hours, possibly due to 
the formation of fusion-incompetent SNARE intermediates and other unknown factors 
(Pobbati et al., 2006). The fast exocytosis of vesicle content seen in vivo appears to depend 
on the presence of SNARE regulatory proteins such as Munc13, Munc18 and CAPS, which 
are also part of the vesicle fusion machinery. 
 
1.5.2 Munc18 
 Mammalian uncoordinated-18 (Munc18) belongs to the family of Sec1/Munc18 (SM) 
proteins. This family of proteins is known to function in conjunction with SNARE proteins in 
diverse cellular membrane trafficking processes. The absence of Munc18 in mice leads to a 
complete block of neurotransmission (Verhage et al., 2000) and almost completely abrogates 
secretion from chromaffin cells (Toonen et al., 2006a). Munc18 is established as a docking 
factor both in autaptic neurons (Toonen et al., 2006b) and in chromaffin cells (Gulyas-
Kovacs et al., 2007). Munc18 expression levels controls the size of the RRP and synapse 
recovery at high activity (Toonen et al., 2006b). 
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 Munc18 binds tightly to the closed conformation of syntaxin-1 (Hata et al., 1993), 
with a Kd of ≈ 1.4 nM when the entire cytoplasmic domain of syntaxin-1 is used (Burkhardt 
et al., 2008). The binary Munc18/closed syntaxin-1 interaction is mediated by binding of the 
concave inner surface formed by domains 1 and 3a of Munc18 to the Habc domain, the 
connecting region and the H3 domain of syntaxin-1 as well as by binding of the outer surface 
of the Munc18 domain 1 to the syntaxin-1 N-peptide (Fig. 1.7) (Burkhardt et al., 2008). 
Similar modes of interactions involving multiple binding sites had been shown in other SM 
proteins and their cognate syntaxins (Burkhardt et al., 2008). When the N-peptide is bound by 
Munc18, SNARE complex formation is inhibited. Thus, the Munc18/closed syntaxin 
complex has been proposed to prevent non-productive or pre-mature SNARE complex 
formation. In addition, the reduction of syntaxin-1 protein levels by around 70% in Munc18-1 
null mutant mice (Toonen et al., 2005; Zhou et al., 2013) and the reciprocal decrease in 
Munc18 levels in a mutant mouse expressing open syntaxin that exhibits reduced Munc18 
affinity (the syntaxin L165A/E166A, or “LE” mutant) suggest that the binary interaction may 
mutually protect both proteins from degradation (Gerber et al., 2008). Apart from binding to 
the closed formation of syntaxin-1, Munc18 also binds to the SNARE complex. It has been 
reported that Munc18 binds to the SNARE complex via its association with the syntaxin-1 N-
peptide and Habc domain (Burkhardt et al., 2008), or to the four-helix bundle of the core 
complex (Dulubova et al., 2003). The former mode of interaction entails that Munc18 must 
dissociate from syntaxin to allow core complex formation, and rebind to the N-peptide after 
core complex formation. Munc18 binding to the SNARE complex probably serves a function, 
e.g. priming, that is distinct from that of its binding to closed syntaxin-1 before the SNARE 
complex is formed. Munc18 may cooperate with the MUN domain of Munc13 proteins 
through weak interactions to accelerate the extraction of the syntaxin-1 SNARE motif from 




Fig. 1.7  Structure of the Munc18a-closed syntaxin1a complex (Burkhardt et al., 2008).  
 
1.5.3 Munc13 
Mammalian uncoordinated homology-13 (Munc13) is a family of proteins that are 
essential for vesicular neurotransmitter release. Mice lacking the major neuronal isoforms 
Munc13-1 and Munc13-2 are not viable outside the uterus. Although the brains of these mice 
show normal cytoarchitecture and hippocampal neurons develop normally in culture, 
hippocampal synapses from Munc13-1/2 double knockout (DKO) mice are devoid of both 
spontaneous and evoked release (Varoqueaux et al., 2002). Drosophila deficient in the 
expression of dunc-13, the orthologue of Munc13 in Drosophila, showed arrested synaptic 
transmission and an accumulation of docked vesicles at the pre-synapse (Aravamudan et al., 
1999). In C. elegans, unc-13 mutants showed a drastic reduction of GABAergic and 
cholinergic transmission, also with accumulation of vesicles (Richmond et al., 1999). The 
conservation of Munc13 function across different species highlights its critical importance in 
synaptic transmission. 
 
1.5.3.1 Domain Structure of Munc13s 
 Thus far, genes encoding five Munc13 isoforms had been identified, namely Munc13-
1, Munc13-2, Munc13-3, Munc13-4 and brain-specific angiogenesis inhibitor-1 associated 
protein (Baiap3) (Augustin et al., 1999b; Betz et al., 1997; Koch et al., 2000; Shiratsuchi et 
al., 1998). Additionally, there are two splice variants of Munc13-2 (ubiquitous, ubMunc13-2 
and brain-specific, bMunc13-2) with alternatively spliced N-termini (Betz et al., 2001). 
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Munc13s are large multi-domain proteins with molecular weights ranging from ≈ 130-250 
kDa. They share similar domain structures (Fig. 1.8) and are characterised by the presence of 
two C-terminal Munc13-homology domains (MHDs), MHD1 and MHD2 (Koch et al., 2000). 
Two C2 domains (C2B and C2C), which are generally known as Ca2+/phospholipid-binding 
domains, flank the region containing the MHD domains. In Munc13-1 and Munc13-2, the 
C2B domain but not C2C, has been shown to bind Ca2+ (Shin et al., 2010). The region 
between the C2B and C2C domains (residue 849-1531), which has been termed MUN 
domain, folds autonomously and has been described as the minimal functional region of 
Munc13s (Basu et al., 2005). However, other studies identified the minimal functional region 
of Munc13 as a fragment that includes the MHD1, MHD2 and C2C domains (Madison et al., 
2005; Stevens et al., 2005). Additional domains present in the N-termini of Munc13-1, 
Munc13-2 and Munc13-3 include a C1 domain, which binds diacylglycerol and phorbol esters 
such as β-phorbol 12,13-dibutyrate (PDBu) and phorbol myristate acetate (PMA) (Betz et al., 
1998) and a conserved Ca2+/calmodulin binding site (Junge et al., 2004; Lipstein et al., 2012). 
Both the C1 domain (Basu et al., 2007; Rhee et al., 2002) and Ca2+/calmodulin-binding sites 
are important in the regulation of short-term synaptic plasticity characteristics of Munc13 
(Junge et al., 2004; Rhee et al., 2002). 
 
Fig. 1.8 Domain structure of Munc13 and CAPS isoforms. 
The C-terminal domains of Munc13-1, -2 and -3 are highly conserved, with 75%-85% 
homology (Augustin et al., 1999b). The N-terminal regions of Munc13s are more divergent. 
Munc13-1 and ubMunc13-2, but not the other isoforms, possess a C2A domain. These two 
isoforms form autoinhibitory homodimers through C2A interactions, which are resolved by 
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the binding of RIM to C2A (Betz et al., 2001; Deng et al., 2011). Munc13-4 and Baiap3 are 
two shorter isoforms that lack the variable N-termini but share the C2B, MUN and C2C 
domains with the other Munc13 isoforms. Baiap3 and Munc13-4 share 34% homology at the 
amino acid sequence level (Koch et al., 2000). Weak but significant homologies had been 
found between the MUN domains of all Munc13 isoforms and subunits of membrane 
tethering complexes, e.g. Sec6, AEX-1 and Vps53, implying that MUN domains may serve 
tethering/docking roles similarly as proteins in other membrane fusion systems (Pei et al., 
2009). 
 
1.5.3.2 Expression Pattern of Munc13s 
The expression of Munc13 mRNA in the adult rat brain is shown in Fig 1.9 (Augustin 
et al., 1999a). Munc13-1, -2 and -3 showed neuron-specific expression in rat brain. Munc13-
1 is expressed throughout many brain regions, with high expression in the olfactory bulb, 
striatum, cerebral cortex, CA regions and dentate gyrus of the hippocampus and cerebellum 
(Fig. 1.9A). Both Munc13-2 and Munc-13-3 show more restricted and seemingly 
complementary distributions, with Munc13-2 expressed mainly in rostral brain regions 
(olfactory bulb, cerebral cortex and CA regions of the hippocampus) (Fig. 1.9B) and 
Munc13-3 in caudal brain regions (cerebellum, brain stem, pons and dentate gyrus of 
hippocampus) (Fig. 1.9C). Protein expression of these three isoforms was found to largely 
match the mRNA expression pattern (Augustin et al., 1999a). In rat, the protein expression of 
all three isoforms in whole rat brains increased developmentally from birth and plateaued at 
post-natal day 15-22 (P15-P22) (Augustin et al., 1999a). Ultrastructurally, Munc13-1 was 
found to be localized to the active zone (Betz et al., 1998).  
The expression of Baiap3 protein in the mouse brain is shown in Fig. 1.10. Baiap3 is 
highly expressed throughout the hypothalamus, in the central, medial and basomedial 
amygdaloid nuclei, paraventricular nucleus of the thalamus, septum, bed nucleus of the stria 
terminalis, the midbrain and the brain stem (Wojcik et al., 2013). Outside the nervous system 
Baiap3 RNA expression has been identified in syncytiotrophoblasts in mouse placenta, 




Fig. 1.9 In situ hybridization showing the expression pattern of Munc13-1, -2 and -3 mRNA 
in the rat brain (Augustin et al., 1999a). Ce, cerebellum; Co, cerebral cortex; Hi, 
hippocampus; IC, inferior colliculus; Mo, medulla oblongata; OB, olfactory bulb; Po, pons; 




Fig. 1.10 Immunostaining showing the expression of Baiap3 in the adult mouse brain 
(Wojcik et al., 2013). PB, parabrachial nucleus; NTS, nucleus tractus solitarius; Hi, 
hippocampus; SC, superior colliculus; IC, inferior colliculus; PAG, periaqueductal gray; LS, 
lateral septum; Th, thalamus; Hy, hypothalamus; BST, bed nucleus of the stria terminalis; 
PV, paraventricular thalamic nucleus; DM, dorsomedial hypothalamic nucleus; VMH, 
ventromedial hypothalamic nucleus; Arc, arcuate nucleus; Ce, central amygdaloid nucleus; 
BLA, basolateral amygdaloid nucleus, anterior part; BMA, basomedial amygdaloid nucleus, 
anterior part; ME, medial amygdaloid nucleus; ACo, anterior corticalamygdaloid nucleus. 
Scale bars equal 1 mm. 
 Munc13-4 protein was detected in rat spleen and lung, but not in the brain (Koch et 
al., 2000). Immunohistochemically, Munc13-4 was found to localise to globet cells of the 
bronchial epithelium and to alveolar type II cells in lung (Koch et al., 2000). Both cell types 
serve secretory functions. Munc13-4 was found to be expressed in a number of hematopoietic 
cells, including cytotoxic T lymphocytes (CTLs), where it was found to localise to cytolytic 
granules at the immunological synapse formed by cytotoxic T lymphocytes (Feldmann et al., 
2003), and neutrophils, where it mediate the exocytosis of neutrophil granules (Pivot-Pajot et 
al., 2008). 
The expression of major Munc13 isoforms was also observed in regions outside of the 
brain. Munc13-1, ubMunc13-2 and trace amounts of Munc13-4, but not bMunc13-2, 
Munc13-3 or Baiap3, were detected at the cholinergic neuromuscular junctions of the mouse 
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diaphragm (Varoqueaux et al., 2005). In mouse retina, punctate staining of Munc13-1, 
bMunc13-2, ubMunc13-2 and Munc13-3 has been observed in the inner plexiform layer 
(IPL), where bipolar cell cells, amacrine cells and ganglion cells form conventional synapses 
(Cooper et al., 2012). In contrast, in the outer plexiform layer (OPL), where photoreceptor 
terminals form specialised ribbon synapses on bipolar cells and horizontal cells, only 
ubMunc13-2 staining was observed. Thus, ubMunc13-2 and bMunc13-2 were found to be 
selectively localised to ribbon synapses and conventional synapses, respectively (Cooper et 
al., 2012). In bovine chromaffin cells, low levels of Munc13-1, ubMunc13-2 and Munc13-3 
have been detected, while bMunc13-2 was not expressed (Zikich et al., 2008). Munc13-1 is 
expressed in pancreatic islets of human, mouse and rat (Sheu et al., 2003). 
 
1.5.3.3 Role of Munc13 Isoforms in Priming and Docking 
 The role of Munc13-1 and Munc13-2 in synaptic transmission has been studied 
extensively using autaptic cultures of mouse hippocampal neurons. Synaptic transmission at 
glutamatergic synapses and GABAergic synapses are either dependent on Munc13-1 or 
Munc13-2. In a given glutamatergic hippocampal neuron, ≈ 90% of synapses are dependent 
on Munc13-1 for transmission, while the remaining synapses are dependent on Munc13-2 
(Rosenmund et al., 2002). GABAergic transmission is not affected in Munc13-1 KO mice 
(Augustin et al., 1999b). GABAergic hippocampal neurons from Munc13-2 KO mice showed 
normal evoked inhibitory post-synaptic current (IPSC) amplitudes, spontaneous miniature 
IPSC (mIPSC) frequencies and amplitudes, while Munc13-1/2 DKO hippocampal neurons 
are completely silent. Together with the absence of post-synaptic defects, these data 
demonstrate that endogenous expression of either Munc13-1 or Munc13-2 suffices to 
maintain normal GABAergic release in an inhibitory hippocampal neuron (Varoqueaux et al., 
2002). Both evoked excitatory post-synaptic current (EPSC) amplitudes and evoked IPSC 
amplitudes can be rescued to near wild-type levels by the expression of either isoform in 
Munc13-1/2 DKO hippocampal neurons, indicating that these two isoforms can be employed 
for release irrespective of neurotransmitter type (Rosenmund et al., 2002). In the above-
mentioned Munc13 KO animals (Augustin et al., 1999b; Varoqueaux et al., 2002), as well as 
in unc-13 mutant C. elegans (Richmond et al., 1999) and dunc-13 null Drosophila 
(Aravamudan et al., 1999), where release was observed to be defective, no clear concomitant 
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defects in docking were detected. Thus, Munc13 was proposed to act in a priming step 
downstream of docking to endow SVs with release competence. 
 More recent studies, where ultrastructural data were generated using high pressure 
freezing (HPF) in place of glutaraldehyde fixation, have reported different results. 
Glutaraldehyde is known to induce vesicle fusion (Smith and Reese, 1980), thus creating 
artefacts. In addition, HPF immobilises tissues in ≈10 ms (Siksou et al., 2009), while 
chemical fixation takes much longer to complete, allowing biological and degradation 
processes to continue for some time (Hammarlund et al., 2007). Using HPF, the number of 
SVs docked (exhibiting a “contact patch” with the plasma membrane) at the AZ in both 
cholinergic and GABAergic motor neurons in unc-13 mutant C. elegans was found to be 
reduced to 16% of wild-type, with accumulation of SVs in the peri-synaptic zone 
(Hammarlund et al., 2007). Spine synapses in hippocampal slices obtained from embryonic 
E18 Munc13-1/2 DKO mice and cultured for 5 weeks displayed almost a complete lack of 
vesicles in direct contact with the plasma membrane, while around half of the vesicles within 
40 nm from the plasma membrane were docked in WT synapses (Fig. 1.11) (Siksou et al., 
2009). The finding that Munc13 is not only required for priming but also for docking 
suggests that docking and priming may be one and the same molecular process (see section 




Fig. 1.11 Docking is drastically diminished in hippocampal cultured slices from 
Munc13-1/2 DKO mice (Siksou et al., 2009). 
 Munc13-4 is expressed in haematopoietic cells where it mediates priming of a range 
of exocytic vesicles. Mutations in human Munc13-4 cause familial hemophagocytic 
lymphohistiocytosis subtype 3 (FHL3), which is characterised by an overwhelming activation 
of T lymphocytes and macrophages, resulting in multi-systemic inflammation (Feldmann et 
al., 2003). Munc13-4 deficient cells were shown to be defective in the exocytosis of perforin-
containing cytolytic granules from CTLs, although trafficking of lytic granules by 
microtubules to the contact site and morphological docking were not affected.  Thus, 
Munc13-4 was proposed to underlie the priming of lytic granules in CTLs (Feldmann et al., 
2003). Munc13-4 has been characterised as an effector of Rab27a to regulate dense core 
granule secretion of serotonin from platelets (Shirakawa et al., 2004) and lytic granule 
secretion in CTLs (Neeft et al., 2005). It was further shown to mediate secretory lysosome 
exocytosis in mast cells in a Doc2α-dependent manner (Higashio et al., 2008). Munc13-4 is 
also localised to endosomes in CTLs (Menager et al., 2007), where it probably functions 
together with Syntaxin-11 in fusing endosomes in preparation for granule maturation 
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(Boswell et al., 2012). Munc13-4 accelerates SNARE-mediated liposome fusion and 
promotes trans-SNARE complex formation in a Ca2+-dependent manner. Both the Munc13-4 
C2A and C2B domain (analogous to the C2B and C2C domains in Munc13-1,-2 and -3) have 
been described as having specific Ca2+-dependent functions, namely t-SNARE protein 
binding and phosphatidylserine-containing membrane-binding. Munc13-4 with a mutated 
C2A domain cannot accelerate liposome fusion as well as WT Munc13-4, however, a 
mutation in only the C2B domain reduced acceleration to the same degree as the C2AB 
double mutant, indicating that the C2B domain and its Ca2+-dependent membrane-binding 
function play a dominant role in the Munc13-4/Ca2+-dependent acceleration of SNARE-
mediated liposome fusion (Boswell et al., 2012).   
 Although brain-specific angiogenesis inhibitor-1 associated protein 3 (Baiap3) is 
known as a Munc13 isoform, its role in priming has not been described. Baiap3 was first 
identified as a binding partner of brain-specific angiogenesis inhibitor-1 (BAI-1) (Shiratsuchi 
et al., 1998), a G protein-coupled receptor enriched in the post-synaptic density that can 
activate both the Rho and extracellular-signal-regulated kinase (ERK) pathways (Stephenson 
et al., 2013). Baiap3 KO mice show an increase in anxiety that is more prominent in female 
mice, an altered development of tolerance to benzodiazepines in male mice, and an enhanced 
seizure propensity in both sexes (Wojcik et al., 2013). Action potential frequency in the 
hypothalamus, where Baiap3 is strongly expressed, is significantly increased in Baiap3 KO 
mice by ≈ 2.5-fold compared to WT mice. In the human BAIAP3 gene two single-nucleotide 
polymorphism genotypes were identified that significantly correlate with the occurrence of 
benzodiazepine abuse in men, as well as with anxiety in women (Wojcik et al., 2013). Baiap3 
has further been identified as a transcriptional target of EWS-WT1, a chimeric transcriptional 
factor, which causes desmoplastic small round cell tumor, an aggressive malignancy with 
origins from the serosal surfaces of the abdominal peritoneum (Palmer et al., 2002). However 
the molecular function of Baiap3 remains to be identified. 
 Munc13-1 (Ashery et al., 2000) and ubMunc13-2 (Zikich et al., 2008) have been 
shown to enhance priming of LDCVs in bovine chromaffin cells. Endogenous expression 
levels of Munc13-1, ubMunc13-2 and Munc13-3 were shown to be low (Zikich et al., 2008). 
Overexpression of Munc13-1 by Semliki Forest virus in bovine chromaffin cells caused a 
two- to three-fold increase in both the RRP and SRP, and a ≈ 3.6-fold increase in the 
sustained component of release. The ratio between the RRP and SRP sizes, as well as the 
time constants of the two pools was not altered by the overexpression. Treatment with PMA, 
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a phorbol ester, caused membrane recruitment of EGFP-tagged Munc13-1 to the plasma 
membrane but did not further increase secretion. Expression of Munc13-1 with a mutation in 
the C1 domain that abolishes phorbol esters/diacylglycerol binding, was still able to 
significantly enhance release, although only to around 63% for the exocytotic burst and 45% 
for the sustained component of WT Munc13-1 expression (Ashery et al., 2000). Despite the 
large enhancement in exocytosis, no changes to the docking profile and the number of docked 
vesicles were observed, although the criteria for distinguishing docked vesicles were less 
stringent (≤200 nm within the plasma membrane) than in other studies. From these data, the 
authors concluded that overexpression of Munc13-1 affected only the priming of docked 
vesicles to the SRP, assuming a parallel pool model (Ashery et al., 2000). Overexpression of 
ubMunc13-2 in the same cell type caused an even more dramatic enhancement to release, 
amounting to a ≈ 3.8-fold increase in RRP size, ≈ 5-fold increase in SRP size and ≈ 5-fold 
increase in the sustained component (Zikich et al., 2008). The fast time constant was 
unaltered, but a longer slow time constant was observed in ubMunc13-2 overexpressing cells, 
which was attributed to the slowness of maturation of vesicles to reach release competence 
rather than to an SRP with intrinsically slow release. Overexpression of a calmodulin 
binding-deficient mutant was shown to affect the rate of vesicle replenishment at high [Ca2+], 
but not at low [Ca2+]. Thus, it was proposed that although priming by ubMunc13-2 is Ca2+-
dependent, it probably did not involve Ca2+/calmodulin but other Ca2+-binding domains, such 
as the C2B domain. In contrast, priming by ubMunc13-2 at high [Ca2+] during ongoing 
activity required Ca2+/calmodulin/ubMunc13-2 interactions (Zikich et al., 2008). 
Interestingly, in Munc13-1 overexpressing cells, the release triggered by a second flash at an 
inter-stimulation interval of 2 min has an amplitude similar to control cells (Ashery et al., 
2000), while in ubMunc13-2 overexpressing cells, the second flash caused still more than 2-
fold enhancement as compared to control, indicating that ubMunc13-2 replenishes releasable 
pools faster than Munc13-1 (Zikich et al., 2008). Munc13-1 has been shown to be 
dispensable for LDCV release in chromaffin cells (Stevens et al., 2005). Recently, 
ubMunc13-2 expression has been demonstrated in PC12 cells and to translocate Ca2+-
dependently to sites that are rich in phosphatidylinositol-4,5-bisphosphate (PIP2), regions that 
are proposed as preferential sites for docking (Honigmann et al., 2013). Using a knockdown 
approach, ubMunc13-2 was shown to be required for DCV release from these cells 
(Kabachinski et al., 2013).  
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Munc13-1 is expressed in pancreatic islets, which contain LDCVs for insulin release. 
Munc13-1 expression is reduced in type-2 diabetes non-obese Goto-Kakizaki and obese 
Zucker fa/fa rats (Sheu et al., 2003). The absence of Munc13-1 in pancreatic β-cells from 
mice was found to abrogate the sustained component of insulin release after a step increase in 
[Ca2+] by Ca2+ uncaging, without affecting the exocytotic burst (Kang et al., 2006). 
Replenishment of the RRP was also retarded in Munc13-1 KO β-cells. Maintenance of 
sustained release in WT mice were found to be partially dependent on endogenous levels of 
diacylglycerol, as the defect in sustained release was present but less severe in β-cells from 
C1 domain mutant mice than in Munc13-1 KO mice (Kang et al., 2006).   
 Munc13-1 was also found to play a role in regulating dense core vesicle (DCV) 
release in hippocampal neurons, where DCVs are released preferentially at synapses rather 
than at extra-synaptic sites (van de Bospoort et al., 2012). In Munc13-1/2 DKO neurons, 
DCV release at synapses was reduced by around 60%, while release at extra-synaptic sites 
was reduced to a lesser extent. This reduction was largely attributed to the absence of 
Munc13-1. Overexpression of Munc13-1 in WT hippocampal neurons preferentially 
increased DCV exocytosis at extra-synaptic sites, without enhancing release at synaptic sites. 
It was concluded from these data that by localising to active zones, Munc13-1 contributes to 
maintaining the preference of release at synapses over extra-synaptic sites (van de Bospoort 
et al., 2012).  
Unc-13 mutant C. elegans displayed reduced neuropeptide release from dorsal cord 
cholinergic motor neurons, with accumulation of DCVs in the ventral nerve cord (Sieburth et 
al., 2007). However, unc-13 was found to be dispensable in Ba2+-evoked release of peptide 
cargo from neurons in C. elegans (Speese et al., 2007). The discrepancy probably arose from 
differences in the preparations used (live animals and cultured neurons), as well as in the 
stimulation regimen (endogenous activity in live animals and Ba2+ stimulation). The 
requirement of unc-13 in DCV release from cell bodies of neurons, at least in C. elegans, 
remains unclear.  
 
1.5.3.4 Proposed Mechanisms of Munc13 Function 
 Munc13 has been proposed to function through opening of syntaxin-1, thus removing 
the autoinhibitory interaction of the syntaxin-1 Habc domain and freeing the synataxin-1 
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SNARE motif for SNARE complex formation. This model was proposed following the 
observation that expression of the open form of syntaxin (Dulubova et al., 1999) in the 
neuromuscular junction can completely rescue evoked EPSC amplitude of unc-13 mutant C. 
elegans, although locomotor activity in these mutants was still largely hampered as compared 
to WT worms, and the frequency of endogenous synaptic events in the presence of Ca2+ was 
rescued to only ≈ 20% of WT levels (Richmond et al., 1999). Subsequent studies reported 
incongruent findings in the same preparation, showing that despite the restoration of a primed 
pool of vesicles to ≈ 70% of WT levels as measured by the application of hyperosmotic 
sucrose, the amplitude of evoked release and frequency of endogenous synaptic events were 
significantly reduced in unc-13/open-syntaxin double mutant worms compared with WT 
levels (McEwen et al., 2006). Using HPF techniques for EM, the open-syntaxin allele was 
found to fully rescue the reduction in docking at the AZ in unc-13 mutant worms, but the 
amplitude of evoked release was still only ≈ 38 % and endogenous fusion events ≈ 26 % that 
of WT (Fig. 1.12). Further, release kinetics in these double mutant worms were slower and 
release was more asynchronous than in WT worms (Hammarlund et al., 2007). The fact that 
open syntaxin is able to almost fully rescue sucrose-evoked release and to fully rescue 
docking, but only partially rescue evoked release amplitudes, supports a view that unc-13 
may serve dual roles in two sequential steps. First, docking requires the opening of syntaxin 
by unc-13. Second, unc-13 is required in a priming step after docking, which may also 
involve unc-13/syntaxin interaction, e.g. mediated by the unc-13 C2C domain (Madison et al., 





Fig. 1.12 Full rescue of docking but incomplete rescue of evoked EPSCs by crossing unc-
13 mutant C. elegans with a mutant expressing open syntaxin (modified from (Hammarlund 
et al., 2007)). 
 The mechanism of how Munc13s open syntaxin is unclear. It has been proposed that 
the MUN domain extracts the SNARE motif from the syntaxin-1/Munc18 closed complex 
through weak interactions to promote SNARE complex formation. Indeed, a mutation 
disrupting the MUN/syntaxin SNARE motif interactions was found to retard the MUN-
mediated acceleration of SNARE complex formation by a Munc18 bound form of syntaxin-1 
(Ma et al., 2011). The MUN domain was also found to bind to membrane-anchored syntaxin-
1/SNAP-25 heterodimers and membrane-anchored SNARE complexes, and had been 
suggested to provide a platform on which syntaxin-1/SNAP-25 heterodimers can be 
assembled (Guan et al., 2008). 
 Munc13s form a tripartite complex with Rab3-interacting molecules (RIMs) and 
Rab3, a family of small synaptic vesicular GTPases (Dulubova et al., 2005). RIM activates 
Munc13 function by resolving Munc13 homodimers formed via mutual C2A domain 
interaction (Deng et al., 2011) by binding to regions around and including the C2A domain 
(residue 3-209 of Munc13-1) with its zinc-finger (ZF) domain (Dulubova et al., 2005). Since 
RIM was found to tether Ca2+ channels to pre-synaptic active zones with its PDZ domain and 
its interaction with RIM-binding protein (RIM-BP) (Kaeser et al., 2011), a multi-protein 
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complex consisting of Munc13, RIM, Rab3 and RIM may tether vesicles close to Ca2+ 
channels and co-localize vesicles with the priming machinery to enable fast, synchronous 
release (Kaeser, 2011).  
  
1.5.3.5 Short-term Synaptic Plasticity Characteristics of Munc13 Isoforms  
 Although both glutamatergic and GABAergic hippocampal synapses can utilize either 
Munc13-1 or Munc13-2 to mediate vesicular neurotransmitter exocytosis (Rosenmund et al., 
2002), the two Munc13 isoforms show vastly different short-term synaptic plasticity 
characteristics. Hippocampal glutamatergic neurons from Munc13-1 KO mice, where 90 % 
of synapses are dependent on Munc13-1, showed an initial depression but delayed facilitation 
of ≈ 170% at steady state not seen in WT when stimulated at 10 Hz. The facilitation observed 
was attributed to the remaining 10 % of synapses that used Munc13-2 as their priming factor. 
Rescue of Munc13-1/2 DKO neurons with viral expression of the two isoforms showed that 
release driven by Munc13-1 showed depression similar to the response in WT cells, while 
release driven by Munc13-2 showed facilitation similar to the response in Munc13-1 KO 
neurons under 10 Hz train stimulation. The inherent difference of the two isoforms was 
further exemplified by the higher degree of short-term augmentation seen in Munc13-2-
expressing as compared to Munc13-1-overexpressing cells, following a 10 Hz high frequency 
train for 5 s (Junge et al., 2004; Rosenmund et al., 2002). Rescue of Munc13-1/2 DKO 
hippocampal neurons with both bMunc13-2 and Munc13-3 showed short-term frequency 
facilitation, but the augmentation seen following a 10 Hz train stimulation in cells rescued 
with Munc13-3 was not as strong as that in bMunc13-3 (Lipstein et al., 2012). These studies 
illustrate the inherent differences of Munc13 isoforms in driving refilling of the RRP and 
synaptic vesicle priming. 
 The augmentation characteristic of ubMunc13-2 was thought to be regulated by the 
Ca2+-binding C2B domain. A C2B mutant that failed to bind Ca2+ abolished 
phosphatidylinositol phosphate (PIP) and PIP2 binding of ubMunc13-2 and showed a loss of 
augmentation after a 10 Hz high frequency train, without affecting the size of the RRP, 
amplitude of evoked EPSC and Ca2+-dependence of evoked EPSC amplitude (Shin et al., 
2010). Based on these findings the authors proposed a model in which high synaptic activity 
increases intracellular [Ca2+] as well as membrane concentrations of PIP and PIP2. 
Subsequently, Ca2+-dependent phospholipid-binding of ubMunc13-2 is activated and 
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recruitment of the protein to the membrane is increased, resulting in augmentation (Shin et 
al., 2010).  
 
1.6 Role of CAPS in Priming and Docking  
Ca2+-dependent activator protein for secretion (CAPS) proteins have been shown to 
be involved in the release of both DCVs (Liu et al., 2008; Speese et al., 2007; Zhou et al., 
2007) and synaptic vesicles (Jockusch et al., 2007). Two isoforms for CAPS exist, namely 
CAPS-1 and CAPS-2. In the rat, CAPS-1 expression is largely restricted to the brain and 
neuroendocrine tissues such as the adrenal gland and the pancreas, whereas CAPS-2 is 
expressed in brain, liver, testis and lung (Speidel et al., 2003). While CAPS-1 is widely 
expressed throughout the brain and CAPS-2 shows expression restricted to selected brain 
regions, immunostaining showed that CAPS-1 and CAPS-2 expression largely complements 
each other (Speidel et al., 2003). In brain, CAPS-1 is developmentally upregulated from E14 
until P20. By comparison, CAPS-2 expression is more stable, with slightly higher expression 
in the embryonic brain than that after birth. Ultrastructurally, CAPS-1 was shown to 
colocalise with LDCVs and also to preferentially localise to asymmetric/glutamatergic axon 
terminals over symmetric/GABAergic terminals (Speidel et al., 2003).  The orthologue of 
CAPS in C. elegans, unc-31, was shown to be involved in the release of neuropeptide-
containing DCVs from ventral cord cholinergic motor neurons (Sieburth et al., 2007), in 
Ba2+-evoked release (Speese et al., 2007) and in Ca2+-evoked release (Zhou et al., 2007) of 
DCV cargo from cultured C. elegans neurons. PMA binding to Munc13s/unc-13 not only 
potentiates SV release, but also DCV release in C. elegans ALA neurons (Zhou et al., 2007). 
Strikingly, the potentiation did not manifest in both unc-31 and unc-13 mutant neurons, 
suggesting that CAPS/unc-31 may act downstream of Munc13/unc-13 in DCV exocytosis 
(Zhou et al., 2007). CAPS was found to be required for docking of DCVs to the plasma 
membrane in C. elegans ventral cord motor neurons. The docking deficiency in unc-31 
mutant worms can be rescued by overexpression of open syntaxin (Hammarlund et al., 2008). 
Similar to their expression in the brain, CAPS-1 and CAPS-2 display developmental 
upregulation and downregulation in the adrenal gland, respectively (Speidel et al., 2005). In 
embryonic CAPS-1 KO chromaffin cells, the spike frequency detected amperometrically 
during high K+ stimulation was reduced, while no defects in capacitance increase following 
step increases in [Ca2+] or trains of depolarisation was observed. It was concluded from this 
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finding that CAPS-1 is associated with the loading of catecholamines to LDCVs (Speidel et 
al., 2005). In flash photolysis of caged Ca2+ experiments in CAPS-1/2 DKO chromaffin cells, 
the RRP was reduced by ≈ 50 %, while the sustained component was nearly absent (Liu et 
al., 2008).  No docking defect accompanied the reduction of LDCV exocytosis. CAPS was 
thus established as a priming factor for LDCV in chromaffin cells (Liu et al., 2008).  CAPS 
have been shown to accelerate the fusion of liposomes with t-SNARE acceptor complexes 
and synaptobrevin-2 in a PIP2-dependent manner (James et al., 2009). Interestingly, 
expression of open syntaxin rescued the defective RRP size in CAPS-1/2 DKO chromaffin 
cells, but not the sustained component, and Munc13-1 overexpression cannot rescue the 
defective RRP size. This latter result supports that Munc13 may act upstream of CAPS (Liu 
et al., 2010). 
While CAPS proteins are essential in LDCV exocytosis, their role in SV exocytosis 
appears may be more species specific. Unc-31 was shown to be dispensable in Ca2+-
dependent SV release from cultured C. elegans neurons (Speese et al., 2007; Zhou et al., 
2007).  In contrast, CAPS appears to be required for SV release in hippocampal neurons from 
mice. In hippocampal neurons from CAPS-1/2 DKO mice, RRP size, evoked EPSC 
amplitude, mEPSC amplitude and frequency was significantly reduced as compared with 
CAPS-2 single KO cells, demonstrating that CAPS-1 is important in SV release (Jockusch et 
al., 2007). No docking defects of SVs in these neurons were observed, consistent with a 
priming role for SV. The RRP size and evoked EPSC amplitudes of CAPS-1/2 DKO neurons 
can be restored after 40 Hz stimulation which causes an increase in intracellular [Ca2+] 
(Jockusch et al., 2007). Overexpression of Munc13-1 in CAPS-1 DKO cells and 
overexpression of CAPS-1 in Munc13-1/2 DKO cells both fail to cross rescue the release 
deficits, which is suggestive of Munc13 and CAPS acting in an interdependent manner in the 
same pathway in the regulation of vesicle exocytosis (Jockusch et al., 2007; Kabachinski et 
al., 2013).   
 
1.7 Scope of the Thesis 
As discussed above, several lines of evidence suggest that Munc13s as well as CAPS 
proteins regulate exocytosis of SVs and LDCVs. However, a deficit in LDCV exocytosis in 
Munc13-deficient chromaffin cells had not been demonstrated. I therefore investigated 
LDCV exocytosis in chromaffin cells lacking the Munc13 isoforms Munc13-1, Munc13-2, 
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Munc13-3 or Baiap3. This study aims at producing a comprehensive analysis of the 
contribution of individual Munc13 isoforms to LDCV release in a well-characterised model 
system, the chromaffin cell, to shed light on a more unified picture of the regulated 




2. Materials and Methods 
2.1 Transgenic Mouse Lines and Genotyping 
Munc13-1 knockout (KO) (Augustin et al., 1999b), Munc13-1/2 double KO (DKO) 
(Varoqueaux et al., 2002), Munc13-3 KO (Augustin et al., 2001), Baiap3 KO (Wojcik et al., 
2013), Munc13-1-EYFP knockin (KI) (Kalla et al., 2006), Munc13-2-EYFP KI and Munc13-
3-EGFP-KI (Cooper et al., 2012) mice have been described before. Tail DNA was obtained 
according to manufacturer’s instructions using the nexttecTM 1-step DNA isolation system 
(nexttecTM Biotechnologie GmbH). Genotyping was performed for each experiment by a 
standard polymerase chain reaction (PCR) (Maniatis, 1982) and modified as described below 
using RedTaq polymerase (Sigma). PCR reactions were prepared by mixing on ice 2 µl of 
10x buffer, 0.5 mM deoxyribonucleotide triphosphates (dNTPs), 5 µM of each primer, 1 µl 
of RedTaq polymerase, 1 µl of template DNA and sufficient H2O to make up a final reaction 
volume of 20 µl. The primer sequences used for each line, the annealing temperature and the 
number of cycles used are shown in Table 2.1. In a typical reaction programme, reactions 
were incubated at 94°C for 3 min for initial DNA denaturation, followed by 3-step cycles 
consisting of denaturation at 94°C for 3 min, annealing at the suitable annealing temperature 
(Tm, see Table 2.1) for 30 s, and extension at 72°C for around 1 min. The number of cycles 
ranged from 30-35 (Table 2.1). The final step is a 72° C incubation for 7 min for final 













WT 5’-CTTACCCATCTGAGAGCCGGAATTCCA-3’ 250 
60 30 5’-CTCCGAGGGGAATGCGCTTCCGTTTCCTG-3’ 
KO 5’- CTTACCCATCTGAGAGCCGGAATTCCA-3’ 230 5’-GAGCGCGCGCGGCGGAGTTGTTGAC-3’ 
Munc13-2 
KO 
WT 5’-CTCCACTGCCCCCTTTTACTGT-3’ 322 
60 30 5’-TCAAGGGACTGTTCTAGCAATGTT-3’ 
KO 5’-CTCCACTGCCCCCTTTTACTGT-3’ 349 5’-GAGCGCGCGCGGCGGAGTTGTTGAC-3’ 
Munc13-3 
KO 









WT 5'-CCAGAAATCCGCAGGCAGTCGTCA -3' 546 
63 34 5'-CAAGGCAACCACCAGCCGCATCTA -3' 




WT 5’-FAM-AGCGCAGCAACGATGAGGTG-3’ 162 
64 30 5’-GAGAGACGGTGGCCTACGGA-3’ 




WT 5’-GATGAGACAGGCATGACCAT-3’ 190 
61 30 5’-ACAGCTAACTCTCCCTGACTGA-3’ 




WT 5’-TCTCTCAGAGGACCAGCGA-3’ 546 
58 30 5’-TGGCACTTCATGGAACATTTAT-3’ 
KI 5’-CATGGTCCTGCTGGAGTTCGTG-3’ 701 5’-TGGCACTTCATGGAACATTTAT-3’ 
Table 2.1. Primer sequences used for genotyping of transgenic mouse lines.  
The presence and sizes of the PCR products were analysed with 2% agarose gels in a 
Tris-borate buffer (0.09 M Tris-borate, 0.002 M ethylenediaminetetraacetic acid (EDTA), pH 
8.0) according to previously established protocols (Maniatis, 1982). For visualising the DNA 
under UV illumination at 312 nm, ethidium bromide was added to the gel at a final 






2.2 Western Blotting 
Western blots were performed according to standard procedures (Maniatis, 1982) with 
modifications as stated below. Perinatal adrenal gland homogenates were made by pooling 
adrenal glands from E18 (Munc13-1 KO, Munc13-1/2 DKO and control littermates) or P0 
animals (Munc13-2 KO, Munc13-3 KO, Baiap3 KO, Munc13-1-EYFP KI, Munc13-2-EYFP 
KI, Munc13-3-EGFP KI and control littermates) with the same genotype using a Potter S 
homogeniser in an ice-cold homogenisation buffer (320 mM glucose, 20 mM HEPES, 2 mM 
EDTA, pH 7.4; 0.5 µg/ml leupeptin, 1 µg/ml aprotinin and 0.1 mM phenylmethylsulfonyl 
fluoride (PMSF) was added immediately prior to use) at 900 rpm for around 45s for each 
sample at 4°C. A custom-made plunger suitable for homogenisation in an eppendorf tube was 
used. Sufficient buffer was used to result in a concentration of a few µg/µl (≈250 µl per 25 
pairs of perinatal adrenal glands). Whole brain samples from E18 or P0 and from adult 
animals were homogenised using plungers and cylinders of appropriate sizes and 1 ml and 10 
ml buffer per brain, respectively. After homogenization, brain samples were centrifuged for 
10 min at 1000 g at 4°C to pellet the nuclear fraction (Graham, 2002) and the resultant post-
nuclear supernatant was used. Proteins were kept on ice whenever possible during the entire 
homogenisation procedure. Protein samples were denatured in Laemmli buffer (30 g/L 
sodium dodecyl sulphate (SDS), 41.7 mM Tris pH 6.8, 1 mM EDTA, 100 g/L sucrose, 50 
mM dithiothrietol (DTT), 0.074% bromophenol blue) by heating at 96°C for 3 min. After 
denaturation, protein samples were immediately placed on ice. Samples containing 20 µg 
protein were separated on a 7.5% gel for SDS-polyacrylaminde gel electrophoresis (SDS-
PAGE). The buffer for the separating gel contained 1.5 M Tris and 0.4 % SDS (pH 8.8). For 
casting a 7.5% separating gel, 2.5 ml 30% bis-acrylamide solution, 2.5 ml separating gel 
buffer, 4.8 ml H2O, 62.5 µl 10% ammonium persulphate and 12.5 µl N, N, N’, N’-
Tetramethylethylenediamine (TEMED) were mixed. The stacking gel buffer contained 0.5 M 
Tris and 0.4% SDS (pH 6.8). To cast the stacking gel, 1.25 ml 30% bis-acrylamide solution, 
2.5 ml stacking gel buffer, 6.05 ml H2O, 62.5 µl 10% ammonium persulphate and 12.5 µl 
TEMED was mixed. The SDS-PAGE running buffer contained 25 mM Tris, 250 mM glycine 
pH 8.3 and 0.1% SDS. After SDS-PAGE, proteins were transferred onto nitrocellulose 
membranes (Millipore) in a transfer buffer (192 mM glycine, 25 mM Tris, 20% methanol) at 
20-25 V for 16 h at 4°C. A 10x TBS buffer (1.37M NaCl, 200 mM Tris-HCl, pH 7.6) was 
used as a stock solution to prepare the membrane blocking buffer, antibody incubation buffer 




with 1x TBS with 0.1% Tween-20 and non-specific epitopes blocked with a solution which 
contained 5% goat serum, 5% dry milk powder, 1x TBS buffer and 0.1% Tween-20 at room 
temperature (RT) for 30 min. Then, primary antibody incubations with the relevant primary 
antibody diluted in the blocking buffer was performed at 4C overnight. An exception was 
made when blotting for Munc13-4, in which 2% donkey serum was used in place of 5% goat 
serum in the blocking step and in antibody incubations, because the Munc13-4 antibody was 
raised in goat. Primary antibodies used were as follows with the indicated dilutions. Munc13-
1 antibody (Cat#126 103, 1:500) and chromogranin A antibody (affinity purified form of 
Cat#259 002, 1:8000) were from Synaptic Systems. Antibodies against ubMunc13-2 (affinity 
purified, batch #52, 1:2000), bMunc13-2 (affinity purified, batch #50, 1:1000), Munc13-3 
(affinity purified, batch #48, 1:500) (Cooper et al., 2012; Varoqueaux et al., 2005) and 
Baiap3 (“SA5990” or “SA5991”, 1:1000) (Wojcik et al., 2013) were raised in the lab 
previously. Munc13-4 antibody (1:250) was from Novus Biologicals (Cat#NB100-41385). 
Green fluorescent protein (GFP) antibody (1:500) was from Roche (Cat#11814460001). 
Valosin-containing protein (VCP) antibody (1:1000) was from BD Transduction Laboratories 
(Cat#612182). Alternatively, an antibody (1:2000), which was a gift from Prof. Thomas 
Südhof, was used for VCP detection. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
antibody (1:25000) was from Abcam (Cat#ab8245). After primary antibody incubation, 
membranes were rinsed once and washed with gentle shaking in a washing buffer (1x TBS, 
5% dry milk powder and 0.1 % Tween-20) 3 times, with the first two washes lasting for 15 
min and the last lasting for 5 min. Secondary antibodies conjugated with horseradish 
peroxidase were used at dilutions between 1:2000 and 1:20000. This was followed by rinsing 
once and washing for 3 times with the washing buffer as above. Membranes were then rinsed 
once and washed for 5 min in 1x TBS buffer with 0.1% Tween-20. After a final wash step by 
rinsing once and washing for 5 min with 1x TBS buffer, membranes were incubated with 
chemiluminescence reagents in the dark. For Munc13-3, SuperSignal West Dura 
Chemiluminescent Substrate (Thermo Scientific, Cat#64705) was used for detection. For 





2.3 Chromaffin Cell Culture 
Cultures of chromaffin cells from perinatal animals were prepared according to 
published protocols (Sorensen et al., 2003). WT littermate animals were used as control, 
except for the experiment involving Munc13-1/2 DKO animals, where animals of different 
genotypes were prepared depending on their availability in a given litter. Adrenal glands 
were excised from E18 embryos (for experiments involving Munc13-1 KO and Munc13-1/2 
DKO animals) or P0 animals (all other experiments) and placed in ice-cold Locke’s solution 
(154mM NaCl, 5.58 mM KCl, 0.84 mM NaH2PO4, 2.14 mM Na2HPO4 and 10 mM glucose).  
From this point onwards, the culture procedure was performed in a sterile environment. 
Glands were incubated in 300 µl papain solution (200 mg/L L-cysteine, 1mM CaCl2, 0.5 mM 
EDTA, 20U papain/ml (Worthington, Cat#LS003127)) in Dulbecco’s Modified Eagle 
Medium, DMEM (Gibco), bubbled in advance for 15 min with carbogen) at 37°C with gentle 
shaking (450 rpm) for 45 min, followed by an inactivation procedure in which an equal 
volume of a stop solution (10% fetal bovine serum (Gibco, Cat#10500-064), 2.5 g/L trypsin 
inhibitor and 2.5 g/L albumin in DMEM(Gibco)) was added and glands were incubated for 5 
min at 37°C. Without disturbing the glands, the mixture was replaced with 160 µl DMEM 
(Linaris, Cat#GMF2143YK) supplemented with 1% insulin-transferrin-selenium-X (ITS-X) 
supplement (Gibco, Cat#51500-056) and 200 U/L penicillin-streptomycin (Gibco, 
Cat#15070-063). Glands were gently triturated with a 200 µl pipette tip until a cell 
suspension was obtained. 50 µl of the cell suspension was placed onto the centre of glass 
coverslips in a 6-well plate. Cells were placed in a humidified incubator at 37°C and 8% CO2 
and allowed to settle onto the coverslips for 30 min and 2 ml supplemented DMEM 
(supplemented with 1% ITS-X and 200 U/L penicillin-streptomycin, as mentioned above) 
were then added into each well. Cells were used on DIV2 and/or DIV3.  
 
2.4 Virus Preparation and Infection 
Rescue experiments of Munc13-1/2 DKO cells with ubMunc13-2 and Baiap3, and 
overexpression of Baiap3 in WT cells by Semliki Forest viral expression were performed as 
follows. A construct containing the ubMunc13-2 open reading frame fused with an enhanced 
green fluorescent protein (EGFP) sequence was cloned into the viral vector pSFV-1 for the 
production of Semliki Forest virus (Ashery et al., 1999). A pSFV-1 construct for the 




EGFP sequence. Since the efficiency for virus infection varied among different viruses and 
among different batches of the same virus, the amount of virus used per well varied from 50-
100 l. As control, an EGFP-expressing virus was used. This virus showed much higher 
efficiency and typically 5 l were added per well. Cells were used from 4 h to 12 h after 
infection. Infected cells were identified by EGFP fluorescence and cells exhibiting similar 
EGFP fluorescence intensities were used.  
 
2.5 Electrophysiological Recordings and Data Analysis 
Patch-clamping in the whole-cell configuration and Ca
2+
 microfluorimetry were 
performed on cultured chromaffin cells according to published protocols (Lindau and Neher, 
1988; Nagy et al., 2002; Naraghi et al., 1998; Neher and Marty, 1982). Recordings were 
obtained at room temperature with Sylgard-coated 4-6M pipettes at a setup equipped with 
HEKA EPC-10 amplifier (HEKA Electronik), a Zeiss Axiovert 200 microscope, a 
Polychrome V monochromator (TILL photonics) and a xenon flash lamp (Rapp 
OptoElectronics).  
The external solution contained 147 mM NaCl, 10 mM 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), 11.1 mM glucose, 2.8 mM KCl, 2 
mM CaCl2, 1 mM MgCl2 and 3 µM tetrodotoxin (TTX) (pH 7.2, osmolarity between 300 and 
310 mOsM). In depolarization experiments, TTX was omitted. In flash photolysis 
experiments, the internal solution contained 109 mM glutamic acid  (Sigma, Cat#49449), 35 
mM HEPES (Sigma, Cat#H3375), 5 mM nitrophenyl-EGTA, 5.65 mM CaCl2, 2 mM Mg-
adenosine 5’-triphosphate (ATP), 0.3 mM Na-guanosine 5’-triphosphate (GTP), 0.205 mM 
fura-4F (Invitrogen), 0.3 mM furaptra (Invitrogen) and 1 mM ascorbic acid (Walter et al., 
2010) (pH 7.2 adjusted with CsOH, osmolarity between 290 and 295 mOsM). The pre-flash 
[Ca
2+
] is  300 to 600 mM (Schonn et al., 2008), and only cells with pre-flash [Ca2+] in this 
range were used for analysis, because the size of the exocytotic burst scales with pre-flash 
[Ca
2+
] (Voets, 2000). In depolarisation experiments, the internal solution contained 111 mM 
glutamic acid, 35.5 mM HEPES, 17 mM NaCl, 1 mM MgCl2, 2 mM Mg-ATP, 0.3 mM Na-
GTP (pH 7.2 adjusted with CsOH, osmolarity  290-295 mOsM), and the same 
concentrations of fura-4F and furaptra as in the flash experiments. The UV-flash stimuli or 
the depolarisation trains were applied to the cell  90s after the whole cell configuration was 
	  	  
45	  	  
obtained. The UV-flash was generated by a xenon lamp (Rapp OptoElectronics). Intracellular 
[Ca2+] was monitored both before and after the flash by applying alternating pulses of 
excitation light at 340 nm and 380 nm using a Polychrome V monochromator (TILL 
photonics) to the cell that had been dialysed with the two ratiometric Ca2+ dyes with different 
Ca2+ affinities, fura-4F and furaptra (Voets, 2000). Emitted light was recorded and the light 
intensity was converted to voltage signals by a photodiode. The area of interest was restricted 
to inside the boundary of the cell. [Ca2+]  were calculated according to a pre-determined Ca2+ 
calibration curve generated by measuring cells that has been dialysed with solutions of 
known [Ca2+] (see below). Capacitance recordings and voltage signals for [Ca2+] 
measurements were acquired using a HEKA EPC-10 amplifier and the software Patchmaster 
(both HEKA Electronik). 
For Ca2+ calibration of the system (Voets, 2000; Walter et al., 2010), solutions with 
different [Ca2+] were used as internal solutions. To obtain defined [Ca2+], the calibration 
solutions contained different concentrations of Ca2+-chelating agents. The osmolarity of the 
solutions was adjusted to ≈300 mOsM by slightly altering the concentrations of glutamic acid 
and HEPES by varying the amount of 2x BP buffer (250 mM L-glutamic acid and 80 mM 
HEPES, pH adjusted to 7.2 with CsOH) added to the solutions. The composition of the 
solutions and the concentration of free Ca2+ ([Ca2+]free) of each solution are listed in Table 
2.2. The final concentrations of each component of the solutions are listed in Table 2.3. After 
dialysis (around 90 s after obtaining whole cell configuration), cells were illuminated with 
excitation light of alternating wavelengths of 340 nm and 380 nm. The light emitted by the 
ratiometric Ca2+ dyes was detected by a photodiode and converted into voltage signals by the 
amplifier. The ratios of the intensities of the emitted light resulting from 340 nm and 380 nm 
excitation were plotted against the [Ca2+] of each solution. [Ca2+] of the solutions were 
calculated using a custom-made macro in the software IgorPro (WaveMetrics). The ratios 
obtained for each solution were fitted to equation (1) 
 (1) 
where f(x) is the ratio of the intensities of emitted light when excited at wavelength 340 nm to 
that at 380 nm at the [Ca2+] x of each calibration solution, KD1, KD2, Hill1 and Hill2 are the 
microscopic dissociation constants and the Hill coefficients of cooperative binding of Ca2+ 
for the two Ca2+ dyes, R1 and R2 are the weightings of the contribution of the two dyes to the 
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ratio and R0 is the ratio when the [Ca2+] is 0. IgorPro was used to find the relationship 
between the ratio and [Ca2+]. 
 Capacitance data were analysed by fitting a sum of two exponentials to the trace from 
the time that the flash was given until 0.5s after. In cases where no satisfactory fit was 
obtained, the time point marking the end of the fitting window (tfit) was shifted manually to 
obtain a satisfactory fit. The time constants of two kinetically distinct release components 
were obtained directly from the fitting. The sizes of the fast burst (BF), the slow burst (BS) 
and rate of release of the sustained component rsus (which is assumed to be constant) were 
calculated according to equations (2)-(4). 
BF = AF*Afit/(AF+AS)  (2) 
BS = AS*Afit/(AF+AS)  (3) 
rsus = (Aend - Afit)/(4-tfit)  (4) 
where Afit is the average amplitude of the capacitance trace during 0.05 s before tfit, Aend is 
that from 3.95s to 4s after the flash, and AF and AS are the respective amplitudes of the 
exponential curves  given by the fitting. Fitting analysis was performed using the software 
AxoGraph (AxoGraph Scientific). For rescue of Munc13-1/2 DKO by Baiap3, traces could 
not be fitted by a sum of exponentials, thus only capacitance increases within 0.5 s after the 
flash (the exocytotic burst) and between 0.5 s to 4 s (to calculate the rate of sustained release) 











Components Volumes of component in each solution (µ l) 
Solution 1 Solution 2 Solution 3 Solution 4 Solution 5 Solution 6 Solution 7 Solution 8 
2x BP  30.7 26.1 24.6 21.5 20.4 19.3 14.7 36.3 
Nucleotides (20 Mg-ATP, 3 Na-GTP) 8 8 8 8 8 8 8 8 
Dye mix (4 fura-4F, 10 furaptra) 6.5 6.5 6.5 6.5 6.5 6.5 6.5 6.5 
BAPTA (100) 16 6.4 3.6 - - - - - 
Ca-BAPTA (100) - 9.6 12.4 - - - - - 
DPTA (100) - - - 30.4 27.6 24.4 16.4 - 
Ca-DPTA (100) - - - 1.6 4.4 7.6 15.6 - 
CaCl2 (100) - - - - - - - 10 
Vitamin C (40) 2 2 2 2 2 2 2 2 
H2O 16.8 21.4 22.9 10 11.1 12.2 16.8 17.2 
Final volume (µl) 80 80 80 80 80 80 80 80 
Calculated [Ca2+]free  0 nM 334.4 nM 757.3 nM 3.906 µM 12.39 µM 24.49 µM 74.63 µM  10.35 mM 
Table 2.2 Composition of solutions used for calcium calibration. The leftmost column lists the stock solutions used as components of solution 
1-8 for calcium calibration. Concentrations of stock solutions were indicated in brackets in unit mM. 2x BP solution is 250 mM L-glutamic acid, 
80 mM HEPES (pH 7.2 with CsOH). ATP = adenosine triphosphate; GTP = guanosine triphosphate; BAPTA = 1,2-bis(o-aminophenoxy)ethane- 





Species Solution 1 Solution 2 Solution 3 Solution 4 Solution 5 Solution 6 Solution 7 Solution 8 
Mg2+ 2 2 2 2 2 2 2 2 
ATP 2 2 2 2 2 2 2 2 
Fura-4F 0.205 0.205 0.205 0.205 0.205 0.205 0.205 0.205 
Furaptra 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
BAPTA 20 20 20 0 0 0 0 0 
DPTA 0 0 0 40 40 40 40 0 
Ca2+ 0 12 15.5 2 5.5 9.5 19.5 12.5 




3. Results  
3.1 Expression of Munc13 Isoforms in the Adrenal Gland 
 Expression levels of each Munc13 isoform in adrenal glands from WT mice and KO 
littermates as control were examined using Western blotting with isoform-specific antibodies 
(Cooper et al., 2012). Munc13-1 KO P0 pups are weak and die within a few hours after birth 
(Augustin et al., 1999b), and mice deficient for both Munc13-1 and Munc13-2 are often 
stillborn (Varoqueaux et al. 2002). Thus, perinatal animals (E18 or P0) were used throughout 
this study, except where indicated otherwise. VCP was used as the loading control for brain 
and adrenal homogenates, because its expression levels are similar in these two organs (Nagy 
et al., 2008; Schonn et al., 2008). GAPDH was used as a loading control for blotting against 
Munc13-4, because the apparent molecular weights of Munc13-4 and VCP are too similar 
(both ≈ 100 kDa). 
 Immunoblotting showed that Munc13-1 was strongly expressed in brains from E18 
WT animals, while in the adrenal gland expression is very weak (Fig. 3.1A). Expression in 
both the brain and adrenal gland were abolished in tissues from littermate Munc13-1 KO 
mice. Truncated protein products of Munc13-1 were detected at ≈ 120 kDa in brains from 
Munc13-1 KO animals (Fig. 3.1A). These were also expressed in adrenal glands from 
Munc13-1 KO mice, but at much lower levels. ubMunc13-2 expression in brain from P0 WT 
animals is strong, and its expression in the adrenal gland is weaker than that in brain but 
readily detectable (Fig. 3.1B). The expression of ubMunc13-2 was abolished in Munc13-2 
KO mice. Truncated products of ≈ 70 kDa could be observed in Munc13-2 KO brains (data 
not shown). They were also expressed in adrenal glands of these mice with weaker 
expression levels. Attempts by my colleagues to characterise these fragments could not 
clearly define their identities, however the N-terminal ubMunc13-2 fragment is thought to be 
non-functional (Cooper et al., 2012). bMunc13-2 expression was observed in P0 WT brain, 
but not detected in P0 WT adrenal glands (Fig. 3.1B).     
 Munc13-3 expression was detected in P0 brain from WT animals but not in adrenal 
glands (Fig. 3.1C). Baiap3 expression was detected in WT P0 brain, was weaker in adrenal 
glands than in brain (Fig. 3.1D), and was abrogated in Baiap3 KO mice. A truncated product 
with a slightly smaller size was observed in P0 Baiap3 KO brain, its expression was not 
easily detectable in adrenal gland but cannot be ruled out, as overnight exposure revealed 
bands of similar sizes as the truncated product detected in brain (Supplementary Fig. 1, 
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overnight exposure). In brain, the expression of this truncated product peaked at P7 and 
decreased until it disappeared in adult mice (Wojcik et al., 2013). Munc13-4 expression could 
be detected in adult WT lung tissues and was abrogated in the Munc13-4 KO mice, while it 
could not be detected in WT adult adrenal glands (Fig. 3.1E). 
   In E18 Munc13-1/2 DKO mice, expression of Munc13-1 and ubMunc13-2 was 
abrogated, while in littermate WT animals, expression of these two isoforms was intact (Fig. 
3.1F). The truncated Munc13-1 and Munc13-2 fragments that were detected in the respective 
single KO lines were also observed in the Munc13-1/2 DKO mice (Fig. 3.1F for Munc13-1 






Fig. 3.1  Expression of Munc13 isoforms by Western blotting. Antibodies used are indicated 
on the left. (A) Expression of Munc13-1 in brain and adrenal glands of E18 Munc13-1 WT 
and KO mice. Asterisk indicates the signal for Munc13-1 protein which is absent in 
homogenates from Munc13-1 KO mice. (B) Expression of ubMunc13-2 and bMunc13-2 in 
brain and adrenal glands of P0 Munc13-2 WT and KO mice. (C) Expression of Munc13-3 in 
P0 Munc13-3 WT and KO mice. (D) Expression of Baiap3 in P0 Baiap3 WT and KO mice. 
(E) Expression of Munc13-4 in lung and adrenal gland in adult Munc13-4 WT and KO mice. 
(F) Expression of Munc13-1 and ubMunc13-2 in brain and adrenal glands of Munc13-1/2 
double WT (DWT) and DKO mice. Asterisk indicates the signal for Munc13-1 protein that is 
absent from Munc13-1/2 DKO mice. (G) Expression of Munc13-1, ubMunc13-2, bMunc13-2 
and Munc13-3 in adrenal glands from P0 WT and littermate KI Munc13-1-EYFP, Munc13-2-
EYFP and Munc13-3-EGFP mice detected by anti-GFP antibody. (H) Expression of 
Munc13-1, ubMunc13-2 and Baiap3 in the adrenal cortex and medulla from adult WT mice. 
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 In the expression analysis described above, different antibodies were used to probe 
the expression levels of the Munc13 isoforms. In order to circumvent differences in antibody 
affinity and directly compare the expression levels of the Munc13-1, Munc13-2 and Munc13-
3 isoforms, Western blotting was performed on adrenal homogenates prepared from P0 
Munc13-1-EYFP, Munc13-2-EYFP, Munc13-3-EGFP KI mice along with their respective 
WT littermates as control using an anti-EGFP antibody (Fig. 3.1G). Expression of the tagged 
Munc13 isoforms was easily detectable in brain homogenates from the respective KI mice. In 
adrenal gland homogenate, only Munc13-2-EYFP was detectable using an anti-EGFP 
antibody, whereas no signal was observed for Munc13-1-EYFP and Munc13-3-EGFP. These 
data confirm that in mouse perinatal adrenal gland ubMunc13-2 is the isoform with the 
highest expression level. 
 Chromaffin cells reside in the adrenal medulla. To test if Munc13-1, ubMunc13-2 and 
Baiap3 are present in the adrenal medulla and/or the adrenal cortex, adrenal cortical and 
medullary homogenates were prepared from adult WT animals. The separation of adrenal 
cortex and medulla by dissection was verified by blotting for chromogranin A (CgA), which 
expresses exclusively in the adrenal medulla but not in the cortex (Hawkins et al., 1989). The 
medullary homogenate was highly enriched in CgA, while there were only low levels of CgA 
in the cortical homogenate, indicating a relatively clean separation of the two types of tissue 
(Fig. 3.1H). Munc13-1 was clearly detected in the medulla, whereas cortical Munc13-1 levels 
appear to be very low. Baiap3 was also mostly present in the medulla, with much lower 
levels detected in the cortical sample. In contrast to this, ubMunc13-2 levels were higher in 
the cortex than in the medulla. Although this experiment used adult adrenal glands, which 
may show a pattern of expression that differs from that of perinatal glands, this suggests that 
Munc13-1 and Baiap3 are predominantly expressed in chromaffin cells, whereas a significant 
fraction of the ubMunc13-2 detected in whole adrenal gland is due to innervation of the 
adrenal cortex by Munc13-2 positive synapses.  
 To check for possible compensatory expression of other Munc13 isoforms as a 
consequence of deletion of a particular isoform, Western blotting for Munc13-1, ubMunc13-
2, bMunc13-2, Munc13-3 and Baiap3 was performed in brain and adrenal gland homogenates 
of Munc13-1, Munc13-2, Munc13-3 and Baiap3 single KO animals (Supplementary Fig. 2). 
No compensatory changes were observed.  
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 In summary, Munc13-1, ubMunc13-2 and Baiap3 are expressed in perinatal adrenal 
glands, and expression is abolished in the respective KO animals. ubMunc13-2 and Baiap3 
expression is high, while Munc13-1 expression is low. The presence of Munc13-1 and 
Baiap3 in the adrenal gland is contributed mainly by expression in the medulla, whereas 
ubMunc13-2 levels are higher in cortex than in medulla. The expression of bMunc13-2, 
Munc13-3 and Munc13-4 was not detected.   
 
3.2 LDCV Exocytosis is Intact in Munc13-1 KO Chromaffin Cells 
 Next, to examine the role of individual Munc13 isoforms in LDCV exocytosis, Ca2+-
triggered fusion of LDCVs with the plasma membrane was monitored using capacitance 
recordings in chromaffin cells after flash photolysis of caged Ca2+. Capacitance traces 
obtained from littermate E18 Munc13-1+/+ (n = 41) and Munc13-1-/- (n = 45) chromaffin cells 
are shown in Fig. 3.2A, B. Averaged traces from the two groups were overlaid for 
comparison in Fig. 3.2C. Intracellular [Ca2+] before and after the flash did not differ 
significantly between genotypes. The shapes of the averaged traces were similar, except for a 
seemingly larger release from Munc13-1-/- cells. Individual traces normalised at 1s after the 
flash for the two groups superposed each other, showing that the kinetics of release did not 
differ between the two groups (Fig. 3.2D). Upon fitting each trace within 500 ms after the 
flash with a sum of two exponentials the sizes and time constants of individual release 
components were obtained (Fig. 3.2E). The fast burst (112.81 ± 12.22 fF for Munc13-1+/+; 
119.41 ± 10.12 fF for Munc13-1-/-), the rate of sustained release (53.38 ± 4.01 fF/s for 
Munc13-1+/+; 60.07 ± 3.79 fF/s for Munc13-1-/-) and the time constants of the fast and slow 
burst components (fast time constants: 19.00 ± 1.41 ms for Munc13-1+/+, 19.06 ± 1.26 ms for 
Munc13-1-/-; slow time constants: 488.84 ± 49.46 ms for Munc13-1+/+, 499.86 ± 54.09 ms for 
Munc13-1-/-) were not significantly different from each other. However the slow burst 
component of Munc13-1-/- cells was significantly increased by ≈ 24 % (124.99 ± 7.8713 fF 




Fig. 3.2 LDCV exocytosis measured by capacitance changes during flash photolysis of 
caged Ca2+ in E18 Munc13-1+/+ (n = 41) and Munc13-1-/- (n = 45) chromaffin cells. The flash 
occurred at t = 0s. Traces from (A) Munc13-1+/+ cells, (B) littermate Munc13-1-/- cells. (C) 
Averaged [Ca2+] and capacitance traces for both groups before and after the flash. (D) 
Normalised traces within the first second after the flash.  (E) Sizes and time constants of the 
two components of exocytotic burst and rate of sustained release (*, p < 0.05).  
3.3 LDCV Exocytosis is Intact in Baiap3 KO Chromaffin Cells 
Baiap3 is expressed in the medulla of adrenal glands (Fig. 1D, G). To investigate a 
possible role for Baiap3 in priming of releasable LDCVs, exocytosis from P0 Baiap3-/- 
chromaffin cells was examined using littermate Baiap3+/+ cells as control (Fig. 3.3). The 
shapes of capacitance traces from Baiap3+/+ (n = 56) and Baiap3-/- (n = 59) cells were similar, 
and intracellular [Ca2+] before and after the flash did not differ between experimental groups 
(Fig. 3.3A-C). Traces from the two groups normalised at 1s superposed each other, indicating 
that their release kinetics were not different (Fig. 3.3D). Upon fitting by a sum of two 
exponentials, all pool sizes (fast burst: 88.76 ± 6.14 fF for Baiap3+/+, 105.74 ± 8.20 fF for 
Baiap3-/-; slow burst: 134.24 ± 7.29 fF for Baiap3+/+, 142.25 ± 8.16 fF for Baiap3-/-), rate of 
sustained release (53.13 ± 3.44 fF/s for Baiap3+/+; 56.69 ± 3.59 fF/s for Baiap3-/-)  and 
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kinetics of release components (fast time constant: 18.06 ± 0.85 ms for Baiap3+/+, 18.33 ± 
0.94 ms for Baiap3-/-; slow time constant: 390.11 ± 22.97 ms for Baiap3+/+, 464.58 ± 40.69 
ms for Baiap3-/-) were not observed to be significantly different. Thus, Baiap3 is dispensable 
for LDCV release in chromaffin cells triggered by a step increase in [Ca2+].    
 
Fig. 3.3 LDCV exocytosis measured by capacitance changes during flash photolysis of 
caged Ca2+ in P0 Baiap3+/+ (n = 56) and Baiap3-/- (n = 59) chromaffin cells. Traces from (A) 
Baiap3+/+ cells, (B) littermate Baiap3-/- cells. (C) Averaged [Ca2+] and capacitance traces for 
both groups before and after the flash. (D) Normalised traces within the first second after the 
flash.  (E) Sizes and time constants of the two components of exocytotic burst and rate of 
sustained release.  
3.4 LDCV Exocytosis is Intact in Munc13-3 KO Chromaffin Cells  
 Although we did not detect Munc13-3 in P0 WT mouse adrenal glands (Fig. 3.1C), a 
low level of expression has been reported for bovine chromaffin cells (Zikich et al., 2008). 
To test whether Munc13-3 might be present at levels not detectable by our Western blot 
analysis but contribute to LDCV exocytosis in murine chromaffin cells nonetheless, we 
performed capacitance measurements in P0 Munc13-3-/- (n = 51) chromaffin cells using 
littermate Munc13-3+/+ cells (n = 50) as control (Fig. 3.4). LDCV release was intact in 
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Munc13-3 KO chromaffin cells (Fig. 3.4A-C). No differences were observed in pool sizes 
(Fig. 3.4E, fast burst: 83.82 ± 7.12 fF for Munc13-3+/+, 84.35 ± 7.20 fF for Munc13-3-/-; slow 
burst: 98.95 ± 5.98 fF for Munc13-3+/+, 107.25 ± 7.89 fF for Munc13-3-/-), rate of sustained 
release (43.22 ± 3.24 fF/s for Munc13-3+/+; 46.42 ± 2.83 fF/s for Munc13-3-/-) and kinetics of 
release (Fig. 3.4D, E, fast time constant: 18.85 ± 0.92 ms for Munc13-3+/+, 20.35 ± 1.21 ms 
for Munc13-3-/-; slow time constant: 413.21 ± 27.24 ms for Munc13-3+/+, 405.96 ± 29.31 ms 
for Munc13-3-/-) between Munc13-3+/+ and Munc13-3-/- cells. Thus, Munc13-3 is not required 
in LDCV release triggered by a step increase of [Ca2+]. 
 
Fig. 3.4 LDCV exocytosis measured by capacitance changes during flash photolysis of 
caged Ca2+ in P0 Munc13-3+/+ (n = 51) and Munc13-3-/- (n = 50) chromaffin cells. Traces 
from (A) Munc13-3+/+ cells, (B) littermate Munc13-3-/- cells. (C) Averaged [Ca2+] and 
capacitance traces for both groups before and after the flash. (D) Normalised traces within the 
first second after the flash.  (E) Sizes and time constants of the two components of exocytotic 




3.5 ubMunc13-2 is Required for LDCV Exocytosis in Chromaffin Cells and a Role 
for Munc13-1 Becomes Apparent in the Absence of Munc13-2  
 Aside from Baiap3, ubMunc13-2 is the Munc13 isoform with the highest expression 
in perinatal adrenal gland (Fig. 3.1B, F, G). Since deletion of Baiap3 did not have any effect 
on exocytosis in flash photolysis experiments (Fig. 3.3), we focused on analysing the 
function of ubMunc13-2 and Munc13-1 in LDCV exocytosis in chromaffin cells. 
Capacitance measurement during flash photolysis of caged Ca2+ was performed in chromaffin 
cells from E18 littermates that were deficient for either Munc13-1, or for Munc13-2 or for 
both isoforms (Munc13-1/2 DKO) (Fig. 3.5A-E). In this experiment, Munc13-1+/+Munc13-
2+/- and Munc13-1+/-Munc13-2+/- cells were used as control (n = 106). Data were collected 
from genotype groups available for a given litter and were pooled for analysis. A comparison 
of both pre-flash and post-flash [Ca2+] measured from this experiment is shown in 
Supplementary Table 1. Pre-flash [Ca2+] of all experimental groups were not significantly 
different from each other. Post-flash [Ca2+] of the five groups were similar, but some 
exceptions exist. The post-flash [Ca2+] of Munc13-1/2 DKO cells was higher than in control 
cells in later time points in the recordings, but since we could observe a large reduction of the 
rate of sustained release in DKO cells compared to control (see below), the higher post-flash 
[Ca2+] is not expected to affect sustained release significantly compared to the effect of gene 
deletion. The same applies to the comparison between Munc13-1-/-Munc13-2+/- cells and 
Munc13-1+/+Munc13-2-/- cells (see Supplementary Table 1). The post-flash [Ca2+] of 
Munc13-1+/-Munc13-2-/- cells (first post-flash [Ca2+] measurement = 29.98 ± 0.633 µM) were 
significantly lower than control cells (first post-flash [Ca2+] measurement = 34.34 ± 0.73 
µM). The post-flash [Ca2+] differences were within 4.5 µM. Since both Munc13-1+/+Munc13-
2-/- and Munc13-1/2 DKO cells showed large reductions of the rate of sustained release 
compared to controls, and the effect on Munc13-1+/-Munc13-2-/- cells was intermediate 
between them (see below), it appears that genotype differences exerted a larger effect than 
the lower post-flash [Ca2+] in these cells on sustained release. Considering the exocytotic 
burst, since post-flash [Ca2+] of between 10 µM and 60 µM is not expected to affect the size 
of the exocytotic burst and the relative sizes of  RRP and SRP (Voets, 2000), the difference in 
post-flash [Ca2+] observed here is not expected to affect the analysis of the exocytotic burst. 
However, the lower post-flash [Ca2+] in Munc13-1+/-Munc13-2-/- cells probably contributes to 
the slightly longer but not significantly different fast and slow time constants of this group 
compared to other experimental groups (Fig. 3.5G) (Voets, 2000). 
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In Munc13-2 KO cells (Munc13-1+/+Munc13-2-/-, n = 46; Munc13-1+/-Munc13-2-/-, n 
= 36; Munc13-1-/-Munc13-2-/-, n = 66), irrespective of Munc13-1 genotype, a drastic 
reduction in release is observed (Fig. 3.5 C-E) as compared to cells from control animals (n = 
106, Fig. 3.5A) and from Munc13-1-/-Munc13-2+/- animals (n = 42, Fig. 3.5B). Examination 
of overlaid averaged traces from the 5 groups of different genotypes showed that LDCV 
release from the control group and Munc13-1-/-Munc13-2+/- cells were almost identical as 
shown by their near superposition, whereas release from Munc13-2 KO cells was diminished. 
It has been shown by Western blotting that in the Munc13-1/2 DKO mouse line used in this 
experiment, the amount of Munc13-1 expression is reduced in Munc13-1 heterozygous brain 
by ≈ 30-50% as compared to Munc13-1 WT brain (Augustin et al., 1999b; Varoqueaux et al., 
2002) and Munc13-2 expressed in brain heterozygous for Munc13-2 is reduced by  ≈ 50% as 
compared to Munc13-2 WT (Varoqueaux et al., 2002).  In the absence of Munc13-2, cells 
with different Munc13-1 genotypes showed heterogeneous release properties, with slight 
reductions in release that were dependent on the amount of Munc13-1 protein present.  
Upon fitting a sum of two exponentials to individual traces, it was observed that 
deletion of Munc13-2 caused highly significant reductions in the sizes of the fast burst, slow 
burst and sustained release component (Fig. 3.5G, Table 3.1) as compared to the control 
group. The fast bursts of Munc13-1+/+Munc13-2-/-, Munc13-1+/-Munc13-2-/- and Munc13-1/2 
DKO cells were only 40%, 31% and 29% of control cell levels, respectively (all p < 0.001). 
The slow bursts of the above three groups were only 48%, 44% and 34% of control cell 
levels, respectively (all p < 0.001). The rates of sustained release of the three groups were 
reduced even more drastically, and were only 28%, 23% and 13% of control cell levels, 
respectively (all p < 0.001). The kinetics of release from Munc13-2 KO cells was not 
significantly different from control cells (Fig. 3.5G, H, Table 3.1). Since ubMunc13-2, but 
not bMunc13-2, was detected in perinatal adrenal glands, ubMunc13-2 is essential in priming 

















Munc13-1+/+ or +/- 
Munc13-2+/- 72.02 ± 3.75 89.54 ± 3.63 18.92 ± 0.78 454.69 ± 19.64 30.09 ± 1.53 
Munc13-1-/-Munc13-2+/- 74.14 ± 6.31 96.12 ± 5.62 15.81 ± 0.87 445.54 ± 33.37  31.33 ± 1.98 
Munc13-1+/+Munc13-2-/- 28.35 ± 2.97 42.77 ± 3.49 16.53 ± 1.14 398.44 ± 30.63 8.55 ± 0.97 
Munc13-1+/-Munc13-2-/- 22.53 ± 2.21 39.31 ± 3.50 18.55 ± 1.68 480.54 ± 45.13 7.00 ± 0.90 
Munc13-1-/-Munc13-2-/- 21.19 ± 3.63 30.75 ± 2.97 17.67 ± 1.50 434.86 ± 32.43 3.88 ± 0.42 
Table 3.1 Sizes and time constants of the fast burst, slow burst and the rate of sustained 
release for chromaffin cells from mice with different Munc13-1 and Munc13-2 genotypes.  
 
 
Fig. 3.5 LDCV exocytosis as measured by capacitance changes during flash photolysis of 
caged Ca2+ in chromaffin cells from E18 Munc13-1/2 DKO, Munc13-1 KO and Munc13-2 
KO littermates. Traces from (A) Munc13-1+/+Munc13-2+/- and Munc13-1+/-Munc13-2+/- cells 
(n = 106), (B) Munc13-1-/-Munc13-2+/- cells (n = 42), (C) Munc13-1+/+Munc13-2-/- cells (n = 
46), (D) Munc13-1+/-Munc13-2-/- cells (n = 36), and (E) Munc13-1/2 DKO cells (n = 66).  (F) 
Averaged [Ca2+] and capacitance traces for all five groups before and after the flash. (G) 
Sizes and time constants of the two components of exocytotic burst and rate of sustained 
release for all five genotype groups (***, p < 0.001; *, p < 0.05). (H) Normalised traces 
within the first second after the flash.   
 In the single Munc13-1 KO line exocytosis of the SRP or of the sustained component 
was not reduced (Fig. 3.2E). However, in the absence of ubMunc13-2, the deletion of 
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Munc13-1 did result in a reduction of LDCV release (Fig. 3.5G, Table 3.1). The fast bursts of 
Munc13-1+/+Munc13-2-/- cells and that of Munc13-1/2 DKO cells were not significantly 
different, but the slow burst of DKO cells was significantly smaller than in Munc13-
1+/+Munc13-2-/- cells (72% of control levels, p < 0.05, Fig. 3.5G, Table 3.2). The effect was 
stronger for the sustained component, with DKO cells releasing at only 45% of Munc13-
1+/+Munc13-2-/- cells (p < 0.001, Fig. 3.5G, Table 3.2). An intermediate reduction was 
observed for Munc13-1+/-Munc13-2-/- cells compared to the DKO, with DKO cells releasing 
at 55% of Munc13-1+/-Munc13-2-/- cells (p < 0.001, Fig. 3.5G). Table 3.2 illustrates the 
contribution of Munc13-1 to release in the absence of Munc13-2. There were no changes to 
the kinetics of release upon Munc13-1 deletion in the Munc13-2 KO background (Fig. 3.5G, 
H). These data demonstrate that although ubMunc13-2 provides the largest contribution to 
regulating LDCV exocytosis in chromaffin cells, in its absence, Munc13-1 participates in 
priming LDCVs for release, affecting the slow burst and the release of vesicles during 
ongoing stimulation at high intracellular [Ca2+]. 
In Munc13-2-/- 
background 
Fast burst Slow burst Rate of sustained 
release 
Munc13-1+/+ 100 % 100 % 100 % 
Munc13-1+/- ≈ 79 % ≈ 92 % ≈ 82 % 
Munc13-1-/- ≈ 75 % ≈ 72 % ≈ 45 % 
Table 3.2 Relative sizes of the Munc13-1 dependent fast burst, slow burst and rate of 
sustained release in the absence of Munc13-2. Release in Munc13-1+/+Munc13-2-/- 
chromaffin cells was set to 100%.  
 Pool sizes of Munc13-1-/-Munc13-2+/- cells and the rate of sustained release were not 
different from control cells (Fig. 3.5G, Table 3.1). Munc13-1-/-Munc13-2+/- cells showed a 
slightly shorter fast time constant as compared to the control groups (Fig. 3.5G, p < 0.05), but 
a corresponding shift in the normalised trace was not observed (Fig. 3.5H). Due to the 
comparison of multiple genotypes, the data shown in Fig. 3.5 include recordings obtained 
from non-littermates. When recordings of Munc13-1-/-Munc13-2+/- (n = 33) cells and control 
cells (n = 30) that were obtained from littermate animals on the same day were analysed 
separately, their averaged fast time constants (16.02 ± 1.02 ms for Munc13-1-/-Munc13-2+/-; 
18.98 ± 1.77 ms for control, p = 0.1439), as well as pool sizes, slow time constant and rate of 
sustained release, were not significantly different. Thus, the small difference in the fast time 
constant between Munc13-1-/-Munc13-2+/- cells and the control group (Fig. 3.5G) is most 




3.6 ubMunc13-2 is Required for LDCV Release Triggered by Depolarization 
 ubMunc13-2 contributes to a large extent to the priming of LDCVs for exocytosis 
using flash photolysis experiments, which involved a step increase in [Ca
2+
] to tens of 
micromolar levels. In order to confirm its role in LDCV exocytosis using a more 
physiological stimulus, a depolarisation train consisting of six 10 ms depolarisations followed 
by four 100 ms depolarisations to 0 mV was applied to chromaffin cells from P0 Munc13-2
-/-
 
animals and littermate Munc13-2
+/+
 animals to test for release deficits (Fig. 3.6). The first six 
short depolarisations and the longer four depolarisations are thought to deplete the IRP and 





 (n = 63) and Munc13-2
-/-
 (n = 60) cells before, during and after the 
depolarisation train were not significantly different (Fig. 3.6A). Ionic charge was calculated 
by integrating the current recorded during each depolarisation (Supplementary Fig. 3A). The 








 depolarisations (all 10 ms long) were slightly smaller in 
Munc13-2
-/-
 than in Munc13-2
+/+
 cells (p < 0.05). The average amplitude of the ionic current 
measured during the steady state of the first 100 ms depolarisation (2.239 s to 2.249 s after 
the start of recording) was not significantly different between the two groups. Thus, the 
amount of Ca
2+





 cells. Capacitance measurements showed a release deficit in Munc13-2
-/-
 
cells (Fig. 3.6A). The capacitance increases (ΔCm) after the 1st (p < 0.001), 2nd (p < 0.001), 
4
th 
(p < 0.001), 5
th
 (p < 0.01), and 6
th 
(p < 0.001) 10 ms depolarisations, as well as the 1
st





 (p < 0.001) 100 ms depolarisations in Munc13-2
-/-
 cells were significantly 
smaller compared to Munc13-2
-/-
 cells (Fig. 3.6B). Accordingly, the total ΔCm after the train 
is significantly diminished in Munc13-2
-/-
 cells (124.87 ± 10.48 fF) compared to that in 
Munc13-2
+/+
 cells (314.25 ± 16.05 fF, p < 0.001). Thus, deletion of Munc13-2 significantly 
reduces the number of LDCVs that can be released in response to Ca
2+
 influx through Ca
2+
 




Fig. 3.6 Depolarisation of Munc13-2-/- (n = 60) chromaffin cells with littermate Munc13-2+/+ 
(n = 63) cells as control. (A) Averaged [Ca2+], capacitance traces and current traces during 
6x10 ms and 4x100 ms depolarisations to 0 mV. The inset next to the current traces showed 
the first 100 ms depolarisation. (B) ΔCm after each depolarisation, total ΔCm and average 
amplitudes of the ionic currents from 2.239 s to 2.249 s after the start of recording for the two 
groups (***, p < 0.001; **, p< 0.01, *, p < 0.05). 
 
3.7 ubMunc13-2 and Munc13-1 Differentially Rescue LDCV Exocytosis in Munc13-
1/2 DKO Chromaffin Cells 
 To compare the function of ubMunc13-2 and Munc13-1 in the DKO background, 
rescue experiments were performed with both isoforms. First, over-expression of ubMunc13-
2 (n = 36) in Munc13-1/2 DKO cells using Semliki Forest virus was compared with 
overexpression of EGFP (n = 32) as control (Fig. 3.7). Overexpression of ubMunc13-2 
dramatically enhanced release from Munc13-1/2 DKO cells, apparently to levels much higher 
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than in WT cells (Fig. 3.7A-C). In virus-infected cells, using the same [Ca2+] measurement 
protocol as in experiments with uninfected cells, [Ca2+] after the flash decayed much more 
slowly (Fig. 3.7C), which could lead to an increase in the sustained rate of release. In 
addition, post-flash [Ca2+] of EGFP-expressing cells measured at three time points during the 
sustained phase of release was significantly higher than in ubMunc13-2-overexpressing cells 
(p < 0.05). However, this difference can probably be discounted as not having a significant 
effect on experimental outcome, since the amount of exocytosis in ubMunc13-2-
overexpressing cells drastically exceeded that in EGFP-overexpressing cells. Virus infection 
also affected the properties of the cells such that traces obtained from cells with small pool 
sizes, e.g. EGFP-expressing Munc13-1/2 DKO cells, became difficult to analyse by a sum of 
two exponentials (Fig. 3.7E). Thus, only a subset of cells was analysed using two exponential 
fitting. The averaged fast burst in ubMunc13-2-overexpressing cells was 314.24 ± 79.59 fF (n 
= 22), which was much larger than that in control cells (12.38 ± 4.91 fF, n = 6), but the 
difference was statistically not significant due to the small number of traces from EGFP 
expressing cells that could be fitted. The slow burst (ubMunc13-2 cells, 580.53 ± 76.21 fF; 
EGFP cells, 25.05 ± 8.12 fF, p < 0.001) and the rate of sustained release (ubMunc13-2 cells, 
396.49 ± 31.80 fF/s; EGFP cells, 4.00 ± 2.29 fF/s, p < 0.001) were significantly enhanced in 
ubMunc13-2-overexpressing cells. The fast time constant was not altered (ubMunc13-2 cells, 
23.74 ± 3.00 ms; EGFP cells, 22.95 ± 8.61 ms), but the slow time constant was longer in 
ubMunc13-2-overexpressing cells than in control cells (ubMunc13-2 cells, 653.19 ± 124.30 
ms; EGFP cells, 189.41 ± 33.28 ms), although the difference is not significant. The slower 
release of ubMunc13-2 within the first second after the flash was also evident in the overlaid 
normalised traces (Fig. 3.7F). Since not all the traces acquired could be fitted with a sum of 
exponentials, the average of all traces from each group (Fig. 3.7C, ubMunc13-2, n = 36; 
EGFP, n = 32) was fitted with a sum of two exponentials, and the results are shown in Fig. 
3.7G. The parameters obtained showed a similar trend as in the two exponential fitting 
analysis of individual traces. In summary, ubMunc13-2 rescued the release deficit in 
Munc13-1/2 DKO cells, confirming that the defective release in these cells is due to the 
absence of ubMunc13-2. In the presence of large amounts of ubMunc13-2, the slow time 




Fig. 3.7 Rescue of defective release in Munc13-1/2 DKO cells by viral overexpression of 
ubMunc13-2. Capacitance traces from (A) EGFP-overexpressing control cells (n = 32), (B) 
ubMunc13-2 expressing cells (n = 36). (C) Averaged [Ca2+] and capacitance traces from the 
two groups. (D) Averaged [Ca2+] and capacitance traces from cells that can be fitted by a sum 
of two exponentials (ubMunc13-2 cells, n = 22; EGFP cells, n = 6). (E) Sizes of the fast 
burst, slow burst, their time constants and the rate of sustained release from the two groups 
(***, p < 0.001). (F) Capacitance traces normalised at 1s. (G) Pool sizes and time constants 
obtained by fitting a sum of two exponentials to the averaged traces shown in (C). 
 Previous studies have reported that overexpression of ubMunc13-2 in WT bovine 
chromaffin cells results in faster vesicle replenishment than that of Munc13-1 (Ashery et al., 
2000; Zikich et al., 2008). In addition, in hippocampal neurons, Munc13-1 expression causes 
depression in response to 10 Hz stimulation, while ubMunc13-2 expression causes 
facilitation (Junge et al., 2004; Rosenmund et al., 2002). In order to examine the inherent 
differences in priming of LDCVs in a cleaner background devoid of interference of possibly 
competing Munc13 isoforms, rescue of Munc13-1 was performed by viral overexpression in 
Munc13-1/2 DKO cells (Fig. 3.8). Statistical analysis of parameters from exponential fittings 
was not performed in this experiment due to insufficient cell numbers. Munc13-1 
overexpression (n = 17) was compared to EGFP expression (n = 13) and also rescued the 
release deficit in Munc13-1/2 DKO cells (Fig. 3.8A-C). When averaged traces of ubMunc13-
2-overexpressing and Munc13-1-overexpressing cells were overlaid, it was observed that 
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ubMunc13-2 expression caused a larger exocytotic burst and faster sustained release than 
Munc13-1 (Fig. 3.8D). Traces normalised at 1s showed that, in contrast to rescue by 
ubMunc13-2, rescue by Munc13-1 did not demonstrate slower release within the first second 
after the flash (Fig. 3.8E). This suggests that, although the release deficit can be rescued by 
either isoforms, Munc13-1 and Munc13-2 have distinct properties in chromaffin cells that 
differentially affect the efficiency of LDCV recruitment for release, especially the rate of 
maturation of vesicles during ongoing stimulation when [Ca2+] is high.  
 
Fig. 3.8 Rescue of Munc13-1/2 DKO chromaffin cells with viral Munc13-1 overexpression. 
Traces from (A) EGFP-overexpressing cells (n = 13), (B) Munc13-1-overexpressing cells (n 
= 17). (C) Averaged [Ca2+] and capacitance traces from the two groups. (D) Overlay of 
capacitance traces in rescue experiments by ubMunc13-2 and Munc13-1 overexpression. (E) 
Traces normalised at 1 s after the flash for EGFP-overexpressing and Munc13-1-
overexpressing cells (left panel), EGFP-overexpressing cells and ubMunc13-2-
overexpressing cells in the rescue using ubMunc13-2 expression (centre), and a comparison 
of ubMunc13-2-overexpressing and Munc13-1-overexpressing cells (right panel). 
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3.8 Baiap3 is Not Required for LDCV Exocytosis in Chromaffin Cells 
 ubMunc13-2 has a dominant role in priming LDCVs for exocytosis in chromaffin 
cells. Relatively small contributions by other isoforms, like the involvement of Munc13-1, 
could be masked in its presence. To test if Baiap3 plays role in LDCV exocytosis in the 
absence of Munc13-1 and Munc13-2, viral overexpression of Baiap3 in Munc13-1/2 DKO 
cells was performed (Fig. 3.9). A comparison of averaged traces showed that Baiap3 does not 
lead to a significant rescue of the release deficit in Munc13-1/2 DKO cells (Fig. 3.9C). The 
capacitance traces of both Baiap3-overexpressing (n = 33) and EGFP-overexpressing (n = 28) 
cells had small amplitudes, precluding analysis by fitting of sums of exponentials. Hence, the 
ΔCm that occurred within 0.5 s and between 0.5 s to 4s after the flash were measured to 
assess the size of the exocytotic burst and sustained release, respectively (Fig. 3.9D). The 
exocytotic burst and rate of sustained release of Baiap3-overexpressing and control cells were 
not significantly different from each other. Thus, Baiap3 does not rescue the defective release 
in Munc13-1/2 DKO cells and therefore does not appear to function in priming LDCVs for 
release. 
 
Fig. 3.9 Baiap3 overexpression in Munc13-1/2 DKO chromaffin cells. Traces from (A) 
EGFP-overexpressing control cells (n = 28), and (B) Baiap3-overexpressing cells (n = 33). 
(C) Averaged [Ca2+] and capacitance traces from the two groups. (D) ΔCm within the first 
0.5 s after the flash to indicate the size of exocytotic burst and ΔCm from 0.5 s to 4 s after the 
flash to indicate sustained release. 
 To test if Baiap3 has any role in tethering LDCVs in the proximity of Ca2+ channels, 
depolarisation trains were applied (6x10 ms and 4x100 ms to 0 mV, as before) to Baiap3 KO 
cells to elicit release of IRP vesicles. Averaged [Ca2+], capacitance and current traces of 
Baiap3+/+ (n = 116) and Baiap3-/- (n = 103) cells are shown in Fig.3.10A. The total ΔCm after 
the train was significantly increased in Baiap3-/- cells (269.03 ± 10.82 fF) compared to 
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Baiap3+/+ cells (228.64 ± 10.61 fF, p < 0.01, Fig. 3.10B), and significant increases in ΔCm 
was observed in Baiap3-/- cells for the 6th 10 ms depolarisation and the 3rd 100 ms 
depolarisation (both p < 0.05, Fig. 3.10B). However, the integrated ionic current during 
individual depolarisations (p < 0.05, Supplementary Fig. 3B), as well as the averaged 
amplitude of ionic current (p < 0.05, Fig. 3.10B) were found to be mildly but significantly 
increased in Baiap3-/- cells. To rule out the effect of increased Ca2+ influx on priming, 
Baiap3+/+ and Baiap3-/- cells were matched for equal current during the first 100 ms 
depolarisation (Fig. 3.11). After matching, current charge of each depolarisation and the 
average amplitude of ionic current were not significantly different between the two groups 
(Supplementary Fig. 3C, Fig. 3.11B), and no differences were observed in the total ΔCm and 
ΔCm after each depolarisation (Fig. 3.11A, B). Thus, there is no evidence that Baiap3 affects 
the size of the IRP and Baiap3 therefore does not appear to function in localizing LDCVs to 
Ca2+ channels.  
 
Fig. 3.10 Depolarisation stimulation of Baiap3-/- (n = 103) and littermate Baiap3+/+ (n = 
116) cells. (A) Averaged [Ca2+], capacitance and current traces for the two groups. Inset next 
to the current trace showed the first 100 ms depolarisation. (B) ΔCm after each 
depolarisation, total ΔCm, and average amplitude of ionic current between 2.239 s and 2.249 




Fig. 3.11 Depolarisation stimulation of Baiap3-/- (n = 40) and littermate Baiap3+/+ (n = 40) 
cells after matching for equal current influx. (A) Averaged [Ca2+], capacitance and current 
traces for the two groups. Inset next to the current trace showed the first 100 ms 
depolarisation. (B) ΔCm after each depolarisation, total ΔCm and average amplitude of ionic 
current between 2.239 s and 2.249 s after the start of recording. 
 Lastly, to probe whether Baiap3 might negatively affect LDCV exocytosis in a WT 
context, Baiap3 was overexpressed in WT mouse chromaffin cells. Traces from EGFP-
overexpressing (n = 34) and Baiap3-overexpressing (n = 37) WT cells are shown in Fig. 3.12. 
An overlay of averaged traces showed that LDCV exocytosis was very similar in both 
experimental groups. Fitting by a sum of two exponentials was possible for a subset of cells 
(EGFP-overexpressing, n = 27, Baiap3-overexpressing, n = 25). This analysis revealed that 
the sizes of the fast burst (58.57 ± 13.02 fF for EGFP-overexpressing cells; 44.34 ± 11.89 fF 
for Baiap3-overexpressing cells), slow burst (90.90 ± 9.14 fF for EGFP-overexpressing cells; 
126.35 ± 28.89 fF for Baiap3-overexpressing cells) and their time constants (fast time 
constant: 28.12 ± 2.68 ms for EGFP-overexpressing cells, 25.93 ± 3.11 ms for Baiap3-
overexpressing cells; slow time constant: 286.55 ± 27.55 ms for EGFP-overexpressing cells, 
234.39 ± 14.13 ms for Baiap3-overexpressing cells), as well as the rate of sustained release 
(47.19 ± 4.73 fF/s for EGFP-overexpressing cells; 52.20 ± 6.17 fF/s for Baiap3-
overexpressing cells) were not significantly different from each other. Thus, Baiap3 appears 
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to have a function in chromaffin cells that is distinct from the regulation of LDCV 
exocytosis. 
 
Fig. 3.12 LDCV exocytosis as measured by capacitance changes during flash photolysis of 
caged Ca2+ in P0 WT chromaffin cells overexpressing either EGFP (n = 34) or Baiap3 (n = 
37). Traces from (A) EGFP-overexpressing cells, (B) littermate Baiap3-overexpressing cells. 
(C) Averaged [Ca2+] and capacitance traces for both groups before and after the flash. (D) 
Normalised traces within the first second after the flash.  (E) Sizes and time constants of the 
two components of exocytotic burst and rate of sustained release.  
 







 This study is the first to demonstrate a deficit in chromaffin cell LDCV exocytosis in 
the absence of Munc13 isoforms. LDCV exocytosis was most strongly impaired in the 
absence of ubMunc13-2, while the contribution of endogenous Munc13-1 to LDCV 
exocytosis only became apparent in the absence of Munc13-2. Single deletions of other 
Munc13 isoforms, namely Munc13-3 and Baiap3, did not affect LDCV exocytosis in mouse 
chromaffin cells.  
 The comparative analysis of LDCV exocytosis in genetic deletion mutants of the 
various Munc13 isoforms enabled me to show that Munc13s play an essential role in priming 
LDCVs for both fast and ongoing release in chromaffin cells. Major findings of this study are 
that ubMunc13-2 is the dominant isoform involved in priming LDCVs into releasable pools 
in chromaffin cells, and that Munc13-1 is involved in priming vesicles into the SRP and in 
the maturation of LDCVs for release during ongoing stimulation (Fig. 3.5). ubMunc13-2 
alone accounts for ≈ 60% of release from the RRP, ≈ 52% of release from the SRP and 72% 
of ongoing sustained release. By contrast, a role for Baiap3, a Munc13 isoform with 
prominent expression in the adrenal medulla, was not evident in my analysis of LDCV 
exocytosis. Although the presence of a functional truncated Baiap3 product in perinatal 
adrenal glands of Baiap3 KO mice cannot be ruled out (Fig. 3.1D, Supplementary Fig. 1), the 
inability of Baiap3 to rescue the release deficit of Munc13-1/2 DKO cells suggests that it 
likely does not function in regulating LDCV exocytosis in chromaffin cells (Fig. 3.9). Since 
bMunc13-2, Munc13-3 and Munc13-4 are not detectable in perinatal adrenal glands (Fig. 
3.1B, C, E), and the abrogation of Munc13-3 caused no significant difference in LDCV 
exocytosis from chromaffin cells (Fig. 3.4), I concluded that the majority of priming in 
chromaffin cells into different kinetic pools is mediated by ubMunc13-2, while Munc13-1 
plays a minor role in mediating release, particularly from the SRP and sustained component. 
 
4.1 Contributions of Munc13 Isoforms to LDCV Exocytosis in Chromaffin Cells 
 The contributions of Munc13 isoforms in LDCV exocytosis in chromaffin cells 
largely correlate with their expression levels in adrenal glands, except for Baiap3. 
ubMunc13-2 and Baiap3 are the most abundant isoforms expressed in the adrenal gland (Fig. 
3.1B, D, F, G, H), while Munc13-1 expression is low (Fig. 3.1A, F, G, H). ubMunc13-2 is 
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largely responsible for priming LDCVs into releasable pools, while Munc13-1 appears to be 
dispensable in a WT genetic background, but its function became apparent upon Munc13-2 
deletion (Fig. 3.5). ubMunc13-2 is important in maintaining normal secretion levels triggered 
by Ca2+ influx, as shown by a marked reduction of release from the IRP and RRP triggered 
by depolarisation trains (Fig. 3.6). bMunc13-2 is not expected to contribute to LDCV 
secretion in chromaffin cells, as its expression cannot be detected in adrenal glands (Fig. 
3.1B). A role of Munc13-3 in LDCV secretion from chromaffin cells is not likely, as its 
expression is undetectable in adrenal glands and flash photolysis experiments showed no 
obvious alterations of secretion from Munc13-3 KO animals (Fig. 3.1C, 3.4). However, since 
the effect of Munc13-1 only became apparent in the absence of Munc13-2, the deletion of 
Munc13-3 in the background of the Munc13-1/2 DKO may be required to unequivocally rule 
out an involvement of Munc13-3 in LDCV exocytosis in mouse chromaffin cells.   
 Overexpression of ubMunc13-2 results in a longer slow time constant in Munc13-1/2 
DKO cells (Fig. 3.7) and in WT cells (Zikich et al., 2008). In the PPM (see section “Vesicle 
Pool Dynamics in Chromaffin Cells”), if post-flash [Ca2+] are similar between control cells 
and ubMunc13-2-overexpressing cells, this would mean that ubMunc13-2 overexpression 
interferes with downstream Ca2+-binding steps of the SRP. How an increase in Munc13 
levels would be able to slow down Ca2+-binding steps is currently unknown.  
 
4.1.1 Contributions of Munc13-1 to LDCV Exocytosis in Chromaffin Cells 
 Abrogation of Munc13-1 alone did not have a major impact on the size of any 
component of release (Fig. 3.2). In the presence of Munc13-2 its contribution to priming into 
the RRP, SRP and for ongoing release appears minor compared to that of ubMunc13-2. 
Compared to Munc13-1+/+Munc13-2+/- and Munc13-1+/-Munc13-2+/- control cells Munc13-1 
contributes maximally to only ≈ 11% of priming into the RRP, ≈ 14% priming into the SRP 
and ≈ 15% of priming for sustained release (% of control levels, Fig. 3.5G). This difference 
can most simply be explained by the much higher expression level in chromaffin cells of 
ubMunc13-2 compared to Munc13-1 (Fig. 3.1A, B, F, G). However, in the absence of 
ubMunc13-2, when setting the release in Munc13-1+/+Munc13-2-/- cells to 100%, it 
contributes to ≈ 30% of the remaining slow burst release and ≈ 55% of the remaining 
sustained release (Table 3.2). Thus, in the absence of Munc13-2, Munc13-1 contributes 
significantly to residual release.	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 In contrast to the effect of Munc13-1 observed in the absence of Munc13-2, no 
reductions in RRP and SRP pool sizes and in sustained release were observed in Munc13-1 
single KO cells, but a mild increase in the SRP occurred instead (p < 0.05, Fig. 3.2). There 
can be two explanations for this phenomenon. First, the higher expression level of 
ubMunc13-2 results in preferential localisation of ubMunc13-2 at the actual release sites, 
such that the removal of Munc13-1 does not impact secretion to a significant degree, because 
most of the release sites are occupied by ubMunc13-2. However, differential localization of 
ubMunc13-2 and Munc13-1 in chromaffin cells has not been shown to date. An alternative 
explanation would thus be that, release site occupancy may not be strongly biased in favour 
of one isoform, but since ubMunc13-2 appears to be more efficient in priming LDCVs in 
chromaffin cells than Munc13-1 (Fig. 3.8), removing Munc13-1 does not affect release 
significantly. Most likely, the differences in expression levels and priming efficiency both 
contribute to the observed effects. Although a direct comparison with WT cells was not made 
experimentally, overexpression of Munc13-1 is able to rescue Munc13-1/2 DKO secretion to 
WT levels (exocytotic burst size in the range of 300-400 fF, Fig. 3.8). However, endogenous 
Munc13-1 in the absence of Munc13-2 is not sufficient to support release to levels similar to 
that of WT (Fig. 3.5). Thus, the low endogenous expression levels of Munc13-1 probably 
contribute to a larger degree than its lower priming efficiency to the release deficit in 
Munc13-1+/+Munc13-2-/- cells. The ability of Munc13-1 overexpression to rescue the release 
deficit of the Munc13-1/2 DKO indicates that Munc13-1 is able to use the release sites 
originally occupied by ubMunc13-2 and is thus a further argument against the existence of 
differential occupation of release sites by ubMunc13-2 and Munc13-1. 
 The apparent increase in the SRP in Munc13-1-/- cells compared to Munc13-1+/+ cells 
(Fig. 3.2E) is difficult to explain. One possible explanation would be, that this reflects the 
occupancy of release sites by the more efficiently priming ubMunc13-2 isoform when 
Munc13-1 is absent, which would again suggest that the two isoforms compete for occupancy 
of release sites (Fig. 3.2E). The effect is however not evident in the comparison between 
Munc13-1+/+Munc13-2+/-/Munc13-1+/-Munc13-2+/- control cells and Munc13-1-/-Munc13-2+/- 
cells (Fig. 3.5G), possibly because in the context of the Munc13-2+/- background only around 




4.2 Priming by Munc13s in the Context of Vesicle Pool Models 
 ubMunc13-2 is important for priming into the RRP, SRP and for sustained release 
(Fig. 3.5), and a significant effect of Munc13-1 on the SRP and sustained release becomes 
apparent in the absence of ubMunc13-2. Since ultrastructural analysis of Munc13-1/2 DKO 
chromaffin cells had not been completed at the time of writing, possible LDCV docking 
defects in chromaffin cells are not discussed here.  
 According to the parallel pool model (PPM) (Voets, 2000; Walter et al., 2013), the 
reduced sizes of the RRP and SRP in cells deficient for Munc13s can be explained by either a 
role of Munc13-dependent priming into the SRP only (or by stabilising the primed SRP 
vesicles) or by Munc13-dependent priming into both the SRP and the RRP (or by stabilising 
both the primed SRP and RRP). According to the PPM, vesicle recruitment from the 
unprimed pool to the SRP is Ca2+-dependent, and the conversion of vesicles from the SRP to 
the RRP is not Ca2+-dependent, at least not at pre-flash [Ca2+] below 600 nM. By contrast, in 
the sequential pool model (SPM) only the RRP is capable of being released, and the SRP 
corresponds to the maturation of non-releasable NRP vesicles to the RRP. Since the effect of 
Munc13 abrogation on the sizes of the RRP and the SRP are similar (reductions to 29% and 
34% of WT levels, respectively), Munc13s may act solely at the Ca2+-dependent priming step 
from the unprimed pool to the SRP. It is however unclear, whether Munc13s play a role in 
priming SRP vesicles into RRP at basal [Ca2+] (< 600 nM) levels and whether or not this step 
is Ca2+-dependent. Simulations using either the PPM or the SPM, which assume Ca2+-
independence and Ca2+-dependence of the (apparent) SRP to RRP conversion, respectively, 
can both recapitulate the recovery of the RRP after its selective depletion using depolarisation 
stimuli (Walter et al., 2013). The same simulation study showed that RRP recovery at high 
[Ca2+] in dual Ca2+-uncaging protocols can be accounted for by the SPM, but in the PPM the 
conversion from the SRP to the RRP would have to be a Ca2+-dependent catalytic process. 
Whether or not Munc13s may function as such a Ca2+-dependent catalyst of SRP to RRP 
conversion remains to be seen. In the calyx of Held, recovery of the RRP from the SRP after 
a short depolarisation pulse which depletes the RRP is mainly dependent on the integrity of 
cytoskeletal transport processes but not on calmodulin or activation of phospholipase C 
(PLC) (Lee et al., 2012; Lee et al., 2013). Ca2+-dependent refilling of the RRP after longer 
depolarisations depleting both the RRP and the SRP is sensitive to calmodulin and PLC 
inhibition. Munc13 is a target of Ca2+/calmodulin signalling and PLC signalling (through its 
Ca2+/calmodulin binding site and C1 domain respectively) (Junge et al., 2004; Rhee et al., 
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2002), and could thus theoretically be involved in the recruitment of RRP vesicles from the 
SRP only after activity dependent increases in [Ca2+] occurs. Ca2+/calmodulin signalling 
through Munc13-1 is important in the fast recovery of the RRP in the calyx (Lipstein et al., 
2013). Thus, Munc13s are involved in the Ca2+-dependent refilling of the RRP in the calyx 
during activity-dependent increases in [Ca2+], which occur in parallel to SRP refilling. 
However, there is no clear evidence that Munc13s are involved in the transition of vesicles 
from the SRP to the RRP under basal, i.e. low [Ca2+] conditions. In chromaffin cells, a study 
by Zikich et al. (2008) showed that in contrast to an 3.8-fold increase in the RRP caused by 
ubMunc13-2 overexpression at high pre-flash [Ca2+], at low pre-flash [Ca2+] (≈ 100 nM) 
overexpression of ubMunc13-2 augments release within the first 100 ms after the flash 
(regarded as the RRP) by only 30% (106 ± 27 fF in ubMunc13-2-overexpressing cells; 74 ± 
11 fF for control cells). Thus, ubMunc13-2 priming into the RRP is accelerated by increased 
[Ca2+], although the enhancement of RRP by ubMunc13-2 overexpression also occurs at low 
pre-flash [Ca2+]. Since at high basal [Ca2+] a 5-fold increase in the SRP parallels the 3.8-fold 
increase in RRP upon ubMunc13-2 overexpression (Zikich et al., 2008), this Ca2+-accelerated 
priming can be accounted for by a role of ubMunc13-2 in priming into the SRP, causing a 
downstream increase in the RRP. Since the effect of ubMunc13-2 abrogation on SRP and the 
RRP reduction is similar, and both rescue of Munc13-1/2 DKO by ubMunc13-2 (Fig. 3.7) 
and overexpression of ubMunc13-2 in WT cells drastically augment both the SRP and RRP 
(Ashery et al., 2000), Munc13s probably act in the priming step into the SRP. In addition, the 
dramatic increase in burst components and sustained release by ubMunc13-2 overexpression 
probably implies that Munc13s actively prime vesicles into the SRP rather than preventing 
vesicles from the SRP from being lost into the unprimed pool. In the PPM, sustained release, 
which is reduced dramatically in the Munc13-1/2 DKO, occurs through the SRP rather than 
the RRP because priming from the SRP to the RRP is slow and Ca2+-independent (Walter et 
al., 2013). By contrast, in the SPM, the effect of Munc13s on sustained release would reflect 
ongoing Ca2+-dependent maturation of previously non-releasable vesicles to the RRP. 
However, since in the SPM, the time constants and amplitudes are interdependent, detailed 
simulation analysis may be required to determine how well the observed effects of Munc13 
deletion fit into the SPM.  	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4.3 Factors That May Mediate Residual Release in Munc13-1/2 DKO Cells 
 In the absence of both ubMunc13-2 and Munc13-1, ≈ 29% of RRP, ≈ 34% of SRP 
and ≈ 13% of sustained release remained. This is unlike the effect of the Munc13-1/2 DKO in 
hippocampal neurons, where SV release was completely abolished (Varoqueaux et al., 2002). 
It is possible that the residual release in chromaffin cells is mediated by CAPS proteins. 
CAPS proteins have an established role in priming LDCVs for release (Liu et al., 2010; Liu 
et al., 2008; Sieburth et al., 2007; Speese et al., 2007; Zhou et al., 2007). They have been 
shown to bind to SNARE proteins and to accelerate SNARE-mediated liposome fusion 
(James et al., 2008; Khodthong et al., 2011). The interaction of CAPS with target membrane 
PIP2 via its pleckstrin homology domain accelerates SNARE-mediated liposome fusion 
(James et al., 2008). Thus, the role of CAPS as a scaffold on which SNARE complexes can 
assemble has been suggested as an aspect of its priming function (James and Martin, 2013). 
In CAPS DKO hippocampal neurons, evoked EPSC amplitude and RRP size are reduced 
substantially, and this reduction can be bypassed transiently by an increase in intracellular 
[Ca2+] (Jockusch et al., 2007). The residual primed vesicles in CAPS DKO neurons have 
been attributed to the presence of Munc13s, because release in CAPS DKO neurons shows 
potentiation after PMA treatment, which has previously been shown to depend on Munc13s. 
Bypass of release reduction in CAPS DKO neurons, mediated by Munc13, required elevated 
intracellular [Ca2+] for a duration of 0.5-2s (Jockusch et al., 2007). Because Munc13-1/2 
DKO neurons are completely silent but CAPS DKO cells can still release Munc13-
dependently, one hypothesis for this observation is that in hippocampal neurons, CAPS 
lowers the Ca2+-dependence or threshold for Munc13-mediated priming. This entails that 
CAPS cannot prime independently without Munc13. However, in the current study, residual 
priming can be observed after deletion of Munc13. One explanation for this may be intrinsic 
differences between chromaffin cells and hippocampal neurons. CAPS alone may be capable 
of priming LDCVs in chromaffin cells but not SVs in hippocampal neurons. How this would 
be achieved at the molecular level is unclear. Nevertheless, subtle differences exist between 
the priming machineries of chromaffin cells and neurons. For instance, chromaffin cells and 
neurons differ in their requirement for the Munc18-1/closed syntaxin complex on docking. In 
mice expressing open syntaxin-1B in the syntaxin-1A KO background, a docking defect was 
observed in chromaffin cells but not in cortical neurons (Gerber et al., 2008). It was thus 
postulated that in neurons, other active zone proteins absent in chromaffin cells mediate 
docking. It is tempting to speculate that the differential equipment of different cell types with 
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Munc13 and CAPS isoforms may shape the Ca2+-dependence of priming. More work is 
required to decipher the nature of this residual priming in Munc13-deficient chromaffin cells 
and to shed light on the complex interdependence of Munc13s and CAPS protein function.   
 
4.4 Possible Mechanisms of Munc13 Function 
4.4.1 Facilitation of SNARE Complex Formation and Tethering of Vesicular 
Membranes 
 What is the molecular function of Munc13 in priming vesicles into releasable pools? 
Neuronal Munc13s have been reported to facilitate the formation of the SNARE complex, 
and various mechanistic models have been suggested. Munc13-4, a non-neuronal isoform, 
accelerates liposome fusion starting with SNAP-25/syntaxin-1 heterodimeric acceptor 
complexes (Boswell et al., 2012). The MUN domain of Munc13s appears to bind both 
membrane-anchored SNARE complexes and membrane-anchored syntaxin-1/SNAP-25 
heterodimers (Guan et al., 2008), and has been shown to accelerate SNARE complex 
formation, starting from Munc18/closed syntaxin-1 complexes (Ma et al., 2011). In this case, 
Munc13 was suggested to extract the C-terminal SNARE motif of syntaxin-1 from the closed 
conformation, thus “opening” syntaxin-1 to allow for SNARE complex formation. Munc13s 
may therefore increase pool sizes by facilitating the formation and stabilisation of t-SNARE 
acceptor complexes on the plasma membrane (an early step in exocytosis) as well as the 
maintenance of primed vesicles on the plasma membrane. Another mechanism not mutually 
exclusive with a role in SNARE complex formation is that Munc13s may tether vesicles in 
the vicinity of release sites. A region around the MHD1 and MHD2 is structurally very 
similar to CATCHR family members (Li et al., 2011). CATCHRs are proteins with a 
membrane tethering role which work in concert with SNARE proteins in diverse cellular 
membrane trafficking reactions (James and Martin, 2013). It would be interesting to see if the 
number of docked vesicles increases when Munc13 is overexpressed, and if increased 
SNARE complex formation in vivo underlies the increase in pool sizes that occurs upon 
Munc13 overexpression. However, the number of SNARE complexes formed per vesicle is 
expected to control the speed of release (Mohrmann et al., 2010; Mohrmann and Sorensen, 
2012). As the speed of release was not increased upon Munc13 overexpression in chromaffin 
cells, this argues against an increase in the number of SNARE complexes formed per vesicle, 
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i.e. there may be another factor that limits the number of SNARE complex that form in the 
presence of excess Munc13. 
 
4.4.2 Munc13 as a Target of PIP2 
 In neurosecretory cells, both syntaxin-1 and SNAP-25 are arranged in supramolecular 
clusters on the plasma membrane (Mohrmann and Sorensen, 2012). Syntaxin-1 clusters are 
maintained by weak homophilic interactions and ionic protein-lipid interactions (Sieber et al., 
2007; van den Bogaart et al., 2011). Both cholesterol and PIP2 have been implicated in 
syntaxin-1 cluster formation, but the clusters that are formed by cholesterol are smaller than 
those by PIP2 (van den Bogaart et al., 2011). The degree of overlap between SNAP-25 and 
syntaxin-1 clusters varies between reports (Lang et al., 2001; Nagy et al., 2005; Rickman et 
al., 2010), but no evidence has been provided that cluster formation hinders heterodimer 
formation (Rickman et al., 2010). In live PC12 cells, t-SNARE heterodimers were reported to 
exist in two configurations, one with a three-helix bundle involving both SNARE motifs of 
SNAP-25 and the other with only one SNAP-25 SNARE motif (Rickman et al., 2010). 
Complexes with these two configurations are spatially segregated from each other on the 
membrane. Since PIP2 clusters and syntaxin-1 clusters colocalise to release sites (van den 
Bogaart et al., 2011), Munc13 may be recruited to these sites by PIP2-C2B domain 
interactions in a Ca2+-dependent manner and facilitate and/or stabilise t-SNARE complex 
configurations that are more favourable for SNARE complex formation. In chromaffin cells, 
the size of the exocytotic burst scales with intracellular [Ca2+] in the nanomolar range. Lawns 
of plasma membrane PIP2 have been reported to control pool sizes but not the time constants 
of release in chromaffin cells (Milosevic et al., 2005). Increasing plasma PIP2 concentrations 
by overexpression of phosphatidylinositol-4-phosphate-5-kinase Iγ or infusion of PIP2 
potentiates release from all secretion components, and conversely expression of an inositol 5-
phosphatase domain of synaptojanin 1 completely abolishes secretion. The latter result 
implies that physiological or basal levels of plasma membrane PIP2 are important for 
secretion in chromaffin cells. Since abrogation of endogenous Munc13 causes pool size-
specific changes and Munc13 recruitment to the plasma membrane is regulated by PIP2 at 
increased [Ca2+] (Kabachinski et al., 2013), Munc13 may be a PIP2 target, regulating pool 
sizes via its C2B domain. Since the lipid microenvironment is thought to pattern the 
distribution of t-SNARE complexes with one vs. two SNAP-25 SNARE motifs (Rickman et 
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al., 2010), it would therefore be interesting to also examine the impact Munc13 levels may 
have on the two populations of t-SNARE heterodimers. 
 
4.5 Possible Functions of Baiap3    
 The function of Baiap3 remains enigmatic. Despite its expression in the adrenal gland 
in perinatal and adult mice (Fig. 3.1D, H), different experimental approaches showed no 
evidence of its positive or negative role in LDCV exocytosis in chromaffin cells (Fig. 3.9-
12). At present, we can only speculate on its possible functions in the adrenal medulla and in 
the brain. 
 Munc13s are characterised by the presence of a MUN domain, which shows weak but 
significant homology to vesicle tethering complexes (Pei et al., 2009). Part of the MUN 
domain was shown to be structurally similar to vesicle tethering factors (Li et al., 2011). 
Hence, Munc13s and tethering factors were suggested to have a common role in membrane 
trafficking events. In phylogenetic trees demonstrating sequence homologies among the 
MUN domains of Munc13s and vesicle tethering factors, Munc13-1, Munc13-2 and Munc13-
3 cluster in the same group, which is distinct from the group where Munc13-4 clusters 
together with Baiap3 (Pei et al., 2009). AEX-1 is a protein in C. elegans that was clustered in 
the same group with Baiap3 and Munc13-4. AEX-1 was documented to locate to muscles 
where it retrogradely stimulates pre-synaptic acetylcholine transmission across the 
neuromuscular junction by altering the localisation of pre-synaptic unc-13 (Doi and Iwasaki, 
2002). Since the prohormone convertase AEX-5 is required for AEX-1 activity, the authors 
proposed that AEX-1 was involved in vesicular exocytosis of a peptidergic signal from 
muscles that modulates pre-synaptic exocytosis.  Interestingly, Baiap3 was initially identified 
in a yeast two-hybrid screen as an interacting partner of the brain-specific angiogenesis 
inhibitor-1 (Shiratsuchi et al., 1998), a seven-span transmembrane receptor which has 
recently been shown to be enriched in the post-synaptic density (Stephenson et al., 2013). 
However, in the brain Baiap3 does not co-localize with the post-synaptic markers of 
glutamatergic or GABAergic synapses, and shows only limited co-localization with pre-




4.5.1 Possible Functions of Baiap3 in the Adrenal Medulla 
 Since Baiap3 does not appear to be present at most glutamatergic or GABAergic 
synapses, it may instead be involved in the release of peptidergic signals to modulate 
neurosecretory behaviour. In chromaffin cells, catecholamine release displays stress-induced 
plasticity, which was inhibited by neuropeptide Y (NPY) in an autocrine manner and possibly 
by other neurons localised in the adrenal medulla, such as NPY-synthesising type I ganglion 
neurons (Holgert et al., 1996; Wang et al., 2013). This plasticity is dependent upon an 
increase in tyrosine hydroxylase (TH) expression to support catecholamine synthesis. 
Interestingly, an increase in TH expression was observed in NPY KO mice, indicating that 
tonic release of NPY exists to control TH levels in chromaffin cells under basal conditions 
(Wang et al., 2013). It has been shown that in chromaffin cells, two populations of LDCVs 
differing in size and the “looseness” of vesicle membranes around the dense core exist 
(Grabner et al., 2005). In addition, although near-simultaneous quantal release of 
catecholamines and NPY has been observed, they represent only a fraction of all events and 
during many events either catecholamines or NPY were released (Whim, 2006). Together 
with a limited overlap of NPY and dopamine β hydroxylase (the enzyme which catalyses the 
formation of norepinephrine from dopamine) immunoreactivity, this indicates that NPY and 
catecholamines can exist in different LDCVs in chromaffin cells (Whim, 2006). In addition, 
background amperometric signals in chromaffin cells were “vanishingly low” (Zhou and 
Misler, 1995), showing that if there is tonic vesicle exocytosis under basal conditions, these 
vesicles do not contain catecholamines. Therefore, Baiap3 may control the regulated or tonic 
release of neuropeptide-containing vesicles from chromaffin cells, which may exhibit release 
properties different from those of catecholamine-containing LDCVs. These vesicles may not 
exist as readily releasable pools, as catecholamine-containing LDCVs do, and their relative 
abundance to catecholamine-containing vesicles has yet to be established. Alternatively, 
Baiap3 may control the release of neuropeptides from type I ganglion neurons in the adrenal 
medulla to modulate catecholamine release from chromaffin cells.  
 
4.5.2 Possible Functions of Baiap3 in the Hypothalamus and Amygdala 
 Baiap3 KO mice showed an increased propensity to pentylenetetrazole (PTZ)-induced 
seizures and an increased novelty-induced anxiety, which mostly manifested as an increased 
freezing response when placed in a novel (fear-conditioning) chamber (Wojcik et al., 2013). 
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In addition, the action potential frequency recorded in the ventromedial nucleus of 
hypothalamic slices of Baiap3 KO mice was increased compared to that of WT mice, 
indicating an increase in basal network activity which is consistent with the increased seizure 
propensitiy. Together with an altered response to benzodiazepines, this suggests an altered 
balance of excitation and inhibition in Baiap3 KO mice. The ventromedial nucleus of the 
hypothalamus is innervated by the anterior, postereodorsal and postereoventral medial 
amydaloid nucleus (Pardo-Bellver et al., 2012). It also receives afferent input from the 
paraventricular nucleus of the hypothalamus and the adjacent posterior part of the bed 
nucleus of stria terminalis (Chen et al., 2011). Most of the above structures also express 
Baiap3 (Wojcik et al., 2013). Since the amygdala and the hypothalamus are implicated in the 
regulation of anxiety and fear responses (Sajdyk et al., 2004), and Baiap3 is expressed 
abundantly in both structures, it may function in regulating the release of neuropeptides in 
these structures. Given that a large number of neuropeptides are involved in mediating 
anxiety and fear responses in the amygdala and hypothalamus, for instance NPY, 
corticotropin-releasing factor, vasopressin, oxytocin, melanin concentrating hormone and 
galanin, to name a few (Alldredge, 2010), there are many possible candidates for Baiap3-
mediated regulation. Baiap3 may be involved in priming, similar to other Munc13 isoforms, 
but since it is only distantly related to the other neuronal isoforms (Munc13-1, Munc13-2 and 
Munc13-3) and possesses the CATCHR domain present in vesicle tethering factors (James 
and Martin, 2013), it may also be involved in mediating other cellular membrane trafficking 
events.  
 
4.6 The Choice of Munc13 Isoforms as Priming Factors in Chromaffin Cells and 
Synapses 
 Our data show that ubMunc13-2 is the dominant Munc13 isoform in the control of 
LDCV pool sizes in chromaffin cells, with Munc13-1 playing a minor role (Fig. 3.5). This is 
obviously distinct from the case of hippocampal glutamatergic neurons, where 
neurotransmitter release from SVs at 90% of synapses depends on Munc13-1 and the 
remainder on Munc13-2 (Rosenmund et al., 2002). What determines the equipment of 
neurosecretory cells with different Munc13 isoforms? Many inherent differences exist in the 
release properties between these two cell types. In hippocampal neurons, a single action 
potential would cause robust synchronous neurotransmitter secretion from SVs in less than 1 
	  	  
81	  	  
ms. In contrast, in chromaffin cells, catecholamine release detected as amperometric spikes 
occurred with delays that are variable between cells (after 2 or 15 action potentials), and 
widely spaced action potentials are relatively ineffective in evoking release (Zhou and Misler, 
1995). Furthermore, in chromaffin cells, the maximum rate of release is ten-fold lower than 
that of a glutamatergic terminal such as the calyx of Held synapse (Neher, 2006). Thus, there 
are significant physiological differences in the excitation-secretion coupling between neurons 
and chromaffin cells. In neurons, exocytosis of SVs is largely limited to specialised active 
zones, whereas DCVs can be released from both synaptic and extrasynaptic sites (van de 
Bospoort et al., 2012). In hippocampal neurons, synaptic DCV release is dependent on 
Munc13s and overexpression of Munc13-1 in synapses shifts the synaptic preference of DCV 
release to extrasynaptic sites (van de Bospoort et al., 2012). The primarily synaptic 
localization of endogenous Munc13-1 and Munc13-2 in neurons thus appears to promote the 
synaptic release of both SVs and DCVs. However, in chromaffin cells LDCV exocytosis can 
occur across the entire cell surface. Chromaffin cells therefore contain more release sites than 
a single synapse allowing pool sizes to be highly modulated (Neher, 2006). Last but not least, 
in addition to depolarisation-induced release through the activation of nicotinic acetylcholine 
(ACh) receptor channels in chromaffin cells, in vivo acetylcholine activates muscarinic ACh 
receptors, which act through PLC activation to release Ca2+ from intracellular Ca2+ stores, 
thus contributing to asynchronous release (Misler, 2009). The distinct release properties of 
chromaffin cells and neurons, although both cell types largely employ the same set of 
proteins, imply that they have different requirements with respect to the vesicle pool refilling 
machinery. As shown in Fig. 3.8, in chromaffin cells ubMunc13-2 is more efficient in 
priming than Munc13-1. This is in agreement with previous findings that pool recovery is 
faster in ubMunc13-2-overexpressing WT chromaffin cells than Munc13-1-overexpressing 
WT cells (Zikich et al., 2008), and with the more prominent short-term enhancement 
mediated by ubMunc13-2 in autaptic hippocampal synapses (Rosenmund et al., 2002). The 
equipment of chromaffin cells with ubMunc13-2 as the dominant priming factor probably 
satisfies the physiological requirements of catecholamine release. While in neurons, highly 
synchronised excitation-secretion coupling is critical for the encoding of information, in 
chromaffin cells a sustained response that allows the release of large amounts of 
catecholamines into the blood when needed is probably more important. The coupling of 
release to action potentials exists in chromaffin cells as well (Zhou and Misler, 1995), but is 
not as tight as in neurons, and release of chatecholamines occurs in bulk into the bloodstream. 
The equipment of chromaffin cells with ubMunc13-2 as the dominant factor in regulating 
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LDCV exocytosis probably ensures that the supply of releasable vesicles is high for increased 
demands. In synapses, instead of providing sufficient vesicles for bulk release, a balance 
between the provision of sufficient vesicles at high synaptic activity and synchronicity of 
release is more important to neurons as components of a computing network.  
 The mild increase of the SRP observed in Munc13-1 KO chromaffin cells may reflect 
the competition between Munc13-1 and ubMunc13-2 in priming LDCVs in chromaffin cells 
(Fig. 3.2). If such a competition exists in neurons, it may be a mechanism by which different 
Munc13 isoforms determine synaptic plasticity characteristics in a given type of neuron. In 
this context, it would be also interesting to examine possible dynamic changes in the 
expression levels of Munc13 isoforms in the brain and in the adrenal gland in vivo under 
pathological conditions or in response to experimental manipulation. However, different 
synapses/neurons have been shown to display functional specialisation in their “usage” of 
Munc13 isoforms. For example, Munc13-2 mediates facilitation in autaptic hippocampal 
cultures (Rosenmund et al., 2002) (assumed to contain predominantly pyramidal cells by 
Breustedt et al., 2010) whereas hippocampal mossy fiber synapses selectively show 
facilitation in the absence of Munc13-2 (Breustedt et al., 2010; Rosenmund et al., 2002). In 
the analysis of the summation of Munc13 effects, it is therefore important to consider the 
expression and subcellular localization of all Munc13 isoforms in a given cell. Another point 
of interest is whether cognate SNARE proteins exist for different Munc13 isoforms, which 
would add another layer of complexity to the system. TIRF microscopy studies have 
demonstrated that granules docked before stimulation, but not newcomer granules, fuse at 
syntaxin-1A clusters (Ohara-Imaizumi et al., 2007). It remains to be demonstrated whether 
Munc13-1 or other Munc13 isoforms preferentially interact with syntaxins other than 
syntaxin-1A. In summary, much additional work is required in trying to find a unifying 
theory on how Munc13 isoforms mediate vesicle priming in general and how they shape 
different forms of synaptic plasticity.   
 
4.7 Significance of Our Findings 
 It had been suggested that CAPS/unc-31 is essential for LDCV exocytosis and 
Munc13s mainly mediates priming of SVs (Augustin et al., 1999b; Liu et al., 2008; Sieburth 
et al., 2007; Speese et al., 2007; Varoqueaux et al., 2002; Zhou et al., 2007). More recently, 
van de Bospoort et al. reported that in hippocampal neurons Munc13s regulate the 
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preferential release of DCVs from synaptic rather than extrasynaptic sites (van de Bospoort et 
al., 2012). The current study establishes ubMunc13-2 as the main LDCV priming factor in 
mouse chromaffin cells and further demonstrates a contribution of endogenous Munc13-1 to 
LDCV exocytosis in this cell type. The absence of ubMunc13-2 has prominent effects on all 
components of release, and is more deleterious than the removal of both isoforms of CAPS. 
A comparison of the effects of Munc13 and CAPS deletion between SV release from 
hippocampal neurons and LDCV release from chromaffin cells shows that the phenotypes are 
in fact relatively similar, with Munc13 being the dominant priming factor and CAPS being 
dispensable under conditions of high [Ca2+]. In CAPS DKO chromaffin cells, the overfilling 
of the SRP triggered by a second flash stimulus is reminiscent of the transient reversal of 
release seen in CAPS DKO hippocampal neurons by increased [Ca2+] (Liu et al., 2008). 
Munc13/CAPS most likely cooperate in both cell types in vesicle pool refilling in a similar 
fashion. Thus, the dichotomy between CAPS priming for LDCVs and Munc13 priming for 
SVs, at least in vertebrates, should not be considered valid and the two types of vesicles may 
have more similar exocytotic machineries than had been thought. In contrast to the large 
release deficits observed in Munc13-2-deficient animals in this study, at least two studies in 
C. elegans reported unperturbed DCV release (of insulin-like cargo and atrial natriuretic 
factor, a neuropeptide) in unc-13 null mutants, implying that in distantly related organisms, 
the employment of priming factors could be somewhat different. Another striking difference 
between C. elegans and mouse, is that unc-31 mutants show a DCV docking deficit that can 
be rescued by open syntaxin, while in CAPS DKO chromaffin cells a docking defect was 
absent and expression of open syntaxin in these cells in turn causes a docking defect 
(Hammarlund et al., 2008; Liu et al., 2010). In addition to the differences that appear to exist 
between species, DCVs represent a diverse group of intracellular organelles with a plethora 
of different cargos, which are released in response to the presence or absence of diverse 
physiological stimuli. Therefore, investigation of individual DCV systems is probably 
required before generalisations can be made with respect to the relative importance of 
similarly functioning components in DCV release. Theoretically, cells that rely mainly on 
priming by Munc13 to regulate pool sizes could be more readily subjected to regulation by 
Ca2+/calmodulin, phorbol esters and plasmalemmal RIM concentrations compared to cells 
mainly reliant on CAPS for priming (e.g. DCVs from C. elegans neurons). With both 
Munc13 and CAPS being involved in priming of both types of vesicles, it would be 
interesting to examine how titrations of these two proteins, whose isoforms are found to show 
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differential expression in the brain and various secretory systems, exert an effect on the Ca2+-
dependence of priming and pool recovery in different systems.   
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Supplementary Fig. 1.  Overnight exposure of the blot showing possible expression of the 
truncated product of Baiap3 at low levels.  
 
 
Supplementary Fig. 2. Expression of Munc13 isoforms in brain and adrenal glands of (A) 
E18 Munc13-1 KO mice, (B) P0 Munc13-2 KO mice, (C) P0 Munc13-3 KO mice, and (D) 












Control      
Munc13-1-/-Munc13-2+/-      
Munc13-1+/+Munc13-2-/-      
Munc13-1+/-Munc13-2-/-      
Munc13-1-/-Munc13-2-/-      	   	  









Control    0.00165  
Munc13-1-/-Munc13-2+/-    0.00964  
Munc13-1+/+Munc13-2-/-    0.04452  
Munc13-1+/-Munc13-2-/-      
Munc13-1-/-Munc13-2-/-      	  









Control    0.00799  
Munc13-1-/-Munc13-2+/-    0.03777  
Munc13-1+/+Munc13-2-/-    0.00282  
Munc13-1+/-Munc13-2-/-     0.00423 
Munc13-1-/-Munc13-2-/-      	  









Control  0.02558  0.00551  
Munc13-1-/-Munc13-2+/-   0.02968  0.00577 
Munc13-1+/+Munc13-2-/-    0.00688  
Munc13-1+/-Munc13-2-/-     0.000158 
Munc13-1-/-Munc13-2-/-      	  









Control  0.02522  0.00193  
Munc13-1-/-Munc13-2+/-   0.00502  0.000417 
Munc13-1+/+Munc13-2-/-    0.000318  
Munc13-1+/-Munc13-2-/-     <0.0001 
Munc13-1-/-Munc13-2-/-      	  









Control  0.01667  0.00290 0.01883 
Munc13-1-/-Munc13-2+/-   0.00162  <0.0001 
Munc13-1+/+Munc13-2-/-    0.00027  
Munc13-1+/-Munc13-2-/-     <0.0001 
Munc13-1-/-Munc13-2-/-      	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Control  0.03230  0.00907 0.01008 
Munc13-1-/-Munc13-2+/-   0.00202  <0.0001 
Munc13-1+/+Munc13-2-/-    0.00058  
Munc13-1+/-Munc13-2-/-     <0.0001 
Munc13-1-/-Munc13-2-/-      	  









Control  0.03509  0.00814 0.00952 
Munc13-1-/-Munc13-2+/-   0.00237  <0.0001 
Munc13-1+/+Munc13-2-/-    0.000421  
Munc13-1+/-Munc13-2-/-     <0.0001 
Munc13-1-/-Munc13-2-/-      	  









Control    0.01443 0.00898 
Munc13-1-/-Munc13-2+/-   0.00306  0.00016 
Munc13-1+/+Munc13-2-/-    0.00040  
Munc13-1+/-Munc13-2-/-     <0.0001 
Munc13-1-/-Munc13-2-/-      
Supplementary Table 1. P-values obtained for differences in pre-flash and post-flash [Ca2+] 
among experimental groups during capacitance measurements to indicate the amount of 
LDCV exocytosis in Munc13-1-/-Munc13-2+/-, Munc13-1+/+Munc13-2-/-, Munc13-1+/-
Munc13-2-/- and Munc13-1/2 DKO cells using Munc13-1+/+/Munc13-1+/-Munc13-2+/- cells as 
control. Values in pink boxes indicate that the group in the left-most column showed a higher 
[Ca2+] than the group in the top row for a given comparison. Values in light green boxes 
indicate that the group in the top row showed a higher [Ca2+] than the group in the left-most 
column.  
 
Supplementary Fig. 3. Ionic charge in each depolarisation for (A) Munc13-2 WT and KO 
cells, (B) Baiap3 WT and KO cells before matching for similar amounts of ionic charge and 
(C) Baiap3 WT and KO cells after matching for similar amounts of ionic charge during the 
first 100 ms depolarisation. 
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